<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="review-article" dtd-version="1.0" xml:lang="hr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LV</journal-id>
<journal-id journal-id-type="nlm-ta">Lijec Vjesn</journal-id>
<journal-title-group>
<journal-title>Lijecnicki Vjesnik</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Lijec. Vjesn.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">0024-3477</issn>
<issn pub-type="epub">1849-2177</issn>
<publisher><publisher-name>Croatian Medical Association</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">LV-145-297</article-id>
<article-id pub-id-type="doi">10.26800/LV-145-9-10-4</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group>
</article-categories>
<title-group>
<article-title>Suvremeni pristup rehabilitaciji oboljelih od Parkinsonove bolesti</article-title>
<trans-title-group xml:lang="en">
<trans-title>Modern approach to the rehabilitation of patients with Parkinson&#x2019;s disease</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Stiperski Matoc</surname><given-names>Matea</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Doko</surname><given-names>Katarina</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Aksentijevi&#x0107;</surname><given-names>Jan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4492-3491</contrib-id><name><surname>Bobek</surname><given-names>Dubravka</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<aff id="aff1"><label>1</label><institution>Zavod za fizikalnu i rehabilitacijsku medicinu s reumatologijom, Klini&#x010D;ka bolnica Dubrava</institution>, <addr-line>Zagreb</addr-line></aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Adresa za dopisivanje: Doc. dr. sc. prim. Dubravka Bobek, dr. med., <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0003-4492-3491">https://orcid.org/0000-0003-4492-3491</ext-link> Zavod za fizikalnu medicinu s reumatologijom, Klini&#x010D;ka bolnica Dubrava, Avenija Gojka &#x0160;u&#x0161;ka 6, 10000 Zagreb, e-po&#x0161;ta: <email xlink:href="procelnik.fizik@kbd.hr">procelnik.fizik@kbd.hr</email></corresp>
<fn fn-type="con">
<p content-type="fn-title">DOPRINOS AUTORA</p>
<p>K<sc>oncepcija</sc> <sc>ili</sc> <sc>nacrt</sc> <sc>rada</sc>: MSM, JA, DB</p>
<p>P<sc>rikupljanje</sc>, <sc>analiza</sc> <sc>i</sc> <sc>interpretacija</sc> <sc>podataka</sc>: MSM, KD</p>
<p>P<sc>isanje</sc> <sc>prve</sc> <sc>verzije</sc> <sc>rada</sc>: MSM</p>
<p>K<sc>riti&#x010D;ka</sc> <sc>revizija</sc>: DB</p>
</fn>
</author-notes>
<pub-date date-type="pub" publication-format="electronic"><month>11</month><year>2023</year></pub-date>
<pub-date date-type="pub" publication-format="print"><month>11</month><year>2023</year></pub-date>
<volume>145</volume>
<issue>9-10</issue>
<fpage>297</fpage>
<lpage>306</lpage>
<permissions>
<copyright-statement>Croatian Medical Association</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Croatian Medical Association</copyright-holder>
<license xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" specific-use="CC BY-NC-ND 4.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.</license-p></license>
</permissions>
<abstract>
<title>SA&#x017D;ETAK</title>
<p>Parkinsonova bolest (PB) je kroni&#x010D;na neurodegenerativna bolest koja se javlja u 2&#x2013;3% populacije starije od 65 godina. U klini&#x010D;koj slici prevladavaju motori&#x010D;ki simptomi poput bradikineze, rigora, tremora, hoda sitnim koracima, posturalne nestabilnosti te smrzavanja hoda. Uz farmakolo&#x0161;ko i kirur&#x0161;ko lije&#x010D;enje, rehabilitacija je neizostavni modalitet lije&#x010D;enja. Sastoji se od fizikalne terapije, radne terapije i terapije govora. Temelj suvremene fizikalne terapije jest aktivni pokret uklju&#x010D;uju&#x0107;i aerobne vje&#x017E;be, vje&#x017E;be s otporom, vje&#x017E;be hoda, vje&#x017E;be ravnote&#x017E;e, vje&#x017E;be s vanjskim vizualnim i auditornim znakovima, <italic>tai chi</italic> i ples. Dokazan je pozitivni u&#x010D;inak vje&#x017E;banja na oporavak motori&#x010D;kih funkcija, hoda, ravnote&#x017E;e te smanjenje u&#x010D;estalosti pada u oboljelih od PB-a.</p>
</abstract>
<trans-abstract xml:lang="en">
<title>SUMMARY</title>
<p>Parkinson&#x2019;s disease (PD) is a chronic neurodegenerative disease that occurs in 2&#x2013;3% of the population over the age of 65. The clinical picture is dominated by motor symptoms such as bradykinesia, rigor, tremors, walking with small steps, postural instability, and freezing of gait. Along with pharmacological and surgical, rehabilitation is a fundamental part of the treatment. It consists of physical therapy, occupational therapy and speech therapy. The basis of modern physical therapy is active movement, including aerobic exercises, resistance exercises, gait exercises, balance exercises, exercises with external visual and auditory cues, Tai Chi and dance. The positive effect of exercise on the recovery of motor functions, gait and balance and the reduction incidence of falls has been proven in patients with PD.</p>
</trans-abstract>
<kwd-group kwd-group-type="author"><kwd>Deskriptori PARKINSONOVA BOLEST &#x2013; dijagnoza, rehabilitacija</kwd><kwd>NEUROLO&#x0160;KI POREME&#x0106;AJI HODA</kwd><kwd>OGRANI&#x010C;ENJE POKRETLJIVOSTI</kwd><kwd>POSTURALNA RAVNOTE&#x017D;A</kwd><kwd>TERAPIJSKE VJE&#x017D;BE &#x2013; metode</kwd><kwd>MODALITETI FIZIKALNE TERAPIJE</kwd><kwd>RADNA TERAPIJA</kwd><kwd>TERAPIJA GOVORA</kwd><kwd>TERAPIJA PLESOM</kwd><kwd>PROCJENA TE&#x017D;INE BOLESTI</kwd></kwd-group>
<kwd-group kwd-group-type="translator" xml:lang="en"><title>Descriptors </title><kwd>PARKINSON DISEASE &#x2013; diagnosis, rehabilitation</kwd><kwd>GAIT DISORDERS, NEUROLOGIC</kwd><kwd>MOBILITY LIMITATION</kwd><kwd>POSTURAL BALANCE</kwd><kwd>EXERCISE THERAPY &#x2013; methods</kwd><kwd>PHYSICAL THERAPY MODALITIES</kwd><kwd>OCCUPATIONAL THERAPY</kwd><kwd>SPEECH THERAPY</kwd><kwd>DANCE THERAPY</kwd><kwd>SEVERITY OF ILLNESS INDEX</kwd></kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="other1">
<title>Epidemiologija</title>
<p>Parkinsonova bolest (PB) je prvi put opisana u eseju o &#x201E;drhtavoj paralizi&#x201C; koji je napisao dr. James Parkinson 1817. godine. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>) Druga je naj&#x010D;e&#x0161;&#x0107;a kroni&#x010D;na neurodegenerativna bolest u svijetu nakon Alzheimerove bolesti. Zahva&#x0107;a 2&#x2013;3% populacije starije od 65 godina, iako se u manjeg broja ljudi javlja i prije 50. godine &#x017E;ivota. (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>) Prevalencija i incidencija PB-a raste sa &#x017E;ivotnom dobi i dose&#x017E;e vrhunac izme&#x0111;u 70. i 79. godine. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) Ve&#x0107;a incidencija PB-a je zabilje&#x017E;ena u mu&#x0161;karaca. U &#x017E;ena je prisutan kasniji po&#x010D;etak bolesti te sporija progresija bolesti. (<xref ref-type="bibr" rid="r4"><italic>4</italic></xref>)</p>
</sec>
<sec sec-type="other2">
<title>Etiopatogeneza</title>
<p>To&#x010D;an uzrok PB-a jo&#x0161; uvijek nije poznat. Razli&#x010D;iti genetski i okoli&#x0161;ni &#x010D;imbenici su povezani s pove&#x0107;anim rizikom nastanka bolesti. Izlo&#x017E;enost pesticidima, vodi iz bunara, &#x017E;ivot u ruralnom podru&#x010D;ju te traumatske ozljede glave su najzna&#x010D;ajniji okoli&#x0161;ni &#x010D;imbenici rizika. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>) S druge strane fizi&#x010D;ka aktivnost, nikotin, kava, alkohol i uporaba nesteroidnih protuupalnih lijekova (NSAID) smanjuju rizik od pojave bolesti. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>, <xref ref-type="bibr" rid="r6"><italic>6</italic></xref>) Javlja se sporadi&#x010D;no. Nasljedni oblik je mnogo rje&#x0111;i te su mutacije gena na&#x0111;ene u 5&#x2013;10% oboljelih. (<xref ref-type="bibr" rid="r7"><italic>7</italic></xref>) Prve su prona&#x0111;ene mutacije alfa-sinukleinskoga gena (SNCA) koji kodira presinapti&#x010D;ki protein &#x03B1;-sinuklein 1996. godine. (<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>, <xref ref-type="bibr" rid="r9"><italic>9</italic></xref>) Od tada su otkrivene razli&#x010D;ite mutacije ve&#x0107;eg broja gena poput mutacije parkina (PARK2), PINK1 (PARK6) i DJ-1 (PARK7) te naj&#x010D;e&#x0161;&#x0107;e mutacije LRRK2 gena (engl. <italic>leucine-rich repeat kinase 2</italic>). Mutacije ve&#x0107;eg broja razli&#x010D;itih gena ukazuju kako je PB heterogena skupina bolesti povezana sli&#x010D;nom patologijom i klini&#x010D;kom slikom. (<xref ref-type="bibr" rid="r7"><italic>7</italic></xref>) Patogeneza PB-a obilje&#x017E;ena je degeneracijom dopaminskih neurona u substanciji nigri s posljedi&#x010D;nim gubitkom njihovih aksona u strijatumu. (<xref ref-type="bibr" rid="r10"><italic>10</italic></xref>) Kada se razine neurotransmitora dopamina smanje za 70% u strijatumu, pojavljuju se motori&#x010D;ki simptomi poput bradikineze, tremora, uko&#x010D;enosti, ataksije i posturalne nestabilnosti. (<xref ref-type="bibr" rid="r11"><italic>11</italic></xref>) Glavna patohistolo&#x0161;ka zna&#x010D;ajka bolesti su Lewyjeva tjele&#x0161;ca, citoplazmatska inkluzijska tjele&#x0161;ca u kojima se talo&#x017E;i alfa-sinuklein, u degeneriranim neuronima i stanicama glije. Lewyjeva tjele&#x0161;ca su na&#x0111;ena i u drugim neurodegenerativnim bolestima poput multiple sistemske atrofije i demencije s Lewyjevim tjele&#x0161;cima koje se zajedni&#x010D;kim imenom nazivaju alfa-sinukleopatije. (<xref ref-type="bibr" rid="r12"><italic>12</italic></xref>)</p>
</sec>
<sec sec-type="other3">
<title>Klini&#x010D;ka slika</title>
<p>U PB-u postoji velik broj razli&#x010D;itih motori&#x010D;kih simptoma. Bradikineza, tj. smanjena brzina i amplituda pokreta ili te&#x0161;ko&#x0107;a u zapo&#x010D;injanju pokreta uvjet je za postavljanje dijagnoze PB-a. Tremor ekstremiteta u mirovanju koji prestaje pri zapo&#x010D;injanju pokreta i rigor prilikom pasivnih kretnji su motori&#x010D;ki simptomi od kojih se barem jedan mora pojaviti za postavljanje dijagnoze. (<xref ref-type="bibr" rid="r13"><italic>13</italic></xref>) Uz navedene, javljaju se i drugi motori&#x010D;ki simptomi poput posturalne nestabilnosti (gubitak posturalnih refleksa u kasnoj fazi bolesti) koja je uz smrzavanje hoda naj&#x010D;e&#x0161;&#x0107;i uzrok pada u oboljelih od PB-a. Smrzavanje hoda je oblik akineze koji karakterizira trenutna prolazna nemogu&#x0107;nost izvr&#x0161;avanja pokreta prilikom zapo&#x010D;injanja koraka ili tijekom hoda. (<xref ref-type="bibr" rid="r14"><italic>14</italic></xref>) Motori&#x010D;ki simptomi se u po&#x010D;etku pojavljuju unilateralno. Ve&#x0107;ina oboljelih od PB-a uz motori&#x010D;ke imaju i nemotori&#x010D;ke simptome poput poreme&#x0107;aja sna, demencije, halucinacija, poreme&#x0107;aja raspolo&#x017E;enja, depresije, ortostatske hipotenzije, urogenitalne disfunkcije, konstipacije te osjetnih poreme&#x0107;aja od kojih je naj&#x010D;e&#x0161;&#x0107;a hiposmija. Nemotori&#x010D;ki simptomi prethode motori&#x010D;kim simptomima godinama te &#x010D;ak desetlje&#x0107;ima ranije. Kroz tijek bolesti postaju sve dominantniji te odre&#x0111;uju kvalitetu &#x017E;ivota i progresiju invalidnosti. (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>)</p>
</sec>
<sec sec-type="other4">
<title>Dijagnoza</title>
<p>Dijagnoza se klini&#x010D;ki postavlja prema kriterijima Me&#x0111;unarodnog dru&#x0161;tva za Parkinsonovu bolest i bolesti pokreta (engl. <italic>Movement Disorder Society Clinical Diagnostic Criteria for Parkinson&#x2019;s disease</italic>). (<xref ref-type="bibr" rid="r15"><italic>15</italic></xref>) U odre&#x0111;enom broju slu&#x010D;ajeva (do 24%) postavi se pogre&#x0161;na dijagnoza multiple sistemske atrofije, progresivne supranuklearne paralize i, rje&#x0111;e, kortikobazalne degeneracije umjesto PB-a. Stoga su va&#x017E;ne dijagnosti&#x010D;ke metode i biljezi koji bi olak&#x0161;ali dijagnozu bolesti u ranoj ili &#x010D;ak prodromalnoj fazi. (<xref ref-type="bibr" rid="r16"><italic>16</italic></xref>) Magnetska rezonancija mozga (engl. <italic>magnetic resonance</italic> &#x2013; MR) nije dovoljna za postavljanje dijagnoze PB-a, ali je korisna u isklju&#x010D;ivanju ishemijskih, upalnih, infektivnih i neoplasti&#x010D;nih uzroka te drugih oblika parkinsonizma. (<xref ref-type="bibr" rid="r17"><italic>17</italic></xref>) Ipak, novije tehnike MR-a poma&#x017E;u u prepoznavanju PB-a. Difuzijski mjereni MR (engl. <italic>diffusion-weighted magnetic resonance imaging</italic> &#x2013; DWI MRI) otkriva abnormalnu difuziju u bazalnim ganglijima i infratentorijalnim strukturama &#x010D;ak i u ranoj fazi bolesti te je koristan za razlikovanje PB-a od multiple sistemske atrofije, progresivne supranuklearne paralize i kortikobazalne degeneracije. (<xref ref-type="bibr" rid="r18"><italic>18</italic></xref>) Emisijska kompjuterizirana tomografija (engl. <italic>single-photon emission computed tomography</italic> &#x2013; SPECT) s radionuklidom (joflupan-123I) razlikuje PB, multiplu sistemsku atrofiju te progresivnu supranuklearnu paralizu od esencijalnog tremora. Pozitronska emisijska tomografija fluorodopom (engl. <italic>positrone emission tomography</italic> &#x2013; PET) tako&#x0111;er razlikuje PB te ostale parkinsonizme s visokom osjetljivosti (75&#x2013;100%) i specifi&#x010D;nosti (87&#x2013;100%). (<xref ref-type="bibr" rid="r19"><italic>19</italic></xref>) Iako je u nekoliko studija pra&#x0107;ena razina razli&#x010D;itih proteina (naj&#x010D;e&#x0161;&#x0107;e &#x03B1;-sinukleina) u cerebrospinalnom likvoru, osjetljivost i specifi&#x010D;nost tih biljega bila je ispod zadovoljavaju&#x0107;e razine te se ne koriste u klini&#x010D;koj praksi. (<xref ref-type="bibr" rid="r20"><italic>20</italic></xref>)</p>
</sec>
<sec sec-type="other5">
<title>Lije&#x010D;enje</title>
<sec>
<title>Konzervativno lije&#x010D;enje</title>
<p>Farmakolo&#x0161;ko lije&#x010D;enje PB-a je isklju&#x010D;ivo simptomatsko. Levodopa je prekursor dopamina te lijek izbora. Zasniva se na nadomje&#x0161;tanju manjka dopamina, &#x010D;ime se posljedi&#x010D;no ubla&#x017E;uju motori&#x010D;ki simptomi. Iako je zlatni standard u lije&#x010D;enju PB-a, kroni&#x010D;na terapija levodopom mo&#x017E;e izazvati motori&#x010D;ke komplikacije. Pojava komplikacija visoko korelira s trajanjem bolesti te trajanjem lije&#x010D;enja i dozom levodope. Nakon &#x010D;etiri do &#x0161;est godina terapije levodopom, motori&#x010D;ke komplikacije se razviju u 40&#x2013;50% oboljelih. U kasnim stadijima bolesti motori&#x010D;ke komplikacije imaju zna&#x010D;ajan u&#x010D;inak na kvalitetu &#x017E;ivota i invaliditeta. Nadalje, s progresijom bolesti javljaju se simptomi koji su rezistentni na u&#x010D;inak levodope poput posturalne nestabilnosti, smrzavanja hoda, pada, disfagije, demencije, psihoze i poreme&#x0107;aja autonomnoga &#x017E;iv&#x010D;anog statusa. Upravo simptomi koji ne odgovaraju na farmakolo&#x0161;ko lije&#x010D;enje jesu glavne odrednice kvalitete &#x017E;ivota, stupnja invalidnosti i na kraju mortaliteta. (<xref ref-type="bibr" rid="r21"><italic>21</italic></xref>)</p>
</sec>
<sec>
<title>Kirur&#x0161;ko lije&#x010D;enje</title>
<p>U kasnijim fazama PB-a, kada se simptomi vi&#x0161;e ne mogu kontrolirati farmakolo&#x0161;ki, postoji mogu&#x0107;nost neurokirur&#x0161;kog lije&#x010D;enja. Metoda izbora je duboka mo&#x017E;dana stimulacija, minimalno invazivni neurokirur&#x0161;ki zahvat koji je zamijenio prethodne invazivne metode. Temelji se na visokofrekventnoj elektri&#x010D;noj stimulaciji u podru&#x010D;ju talamusa, suptalami&#x010D;ke jezgre ili globusa palidusa, ovisno o dominantnim simptomima. (<xref ref-type="bibr" rid="r22"><italic>22</italic></xref>)</p>
</sec>
<sec>
<title>Rehabilitacija</title>
<p>S obzirom na kroni&#x010D;ni progresivni tijek bolesti koji vodi k invaliditetu i smanjenoj kvaliteti &#x017E;ivota, rehabilitacija ima zna&#x010D;ajnu ulogu u lije&#x010D;enju PB-a. (<xref ref-type="bibr" rid="r23"><italic>23</italic></xref>) Uz fizikalnu terapiju, rehabilitacija uklju&#x010D;uje radnu terapiju te terapiju govora i gutanja. Rehabilitacijski tim je multidisciplinaran te ga &#x010D;ine specijalist fizikalne i rehabilitacijske medicine, neurologije, psihijatrije, psiholog, medicinska sestra/tehni&#x010D;ar, fizioterapeut, radni terapeut, logoped, nutricionist i socijalni radnik. (<xref ref-type="bibr" rid="r24"><italic>24</italic></xref>) Primjenom rehabilitacijskih modaliteta posti&#x017E;e se zna&#x010D;ajan napredak u provo&#x0111;enju aktivnosti svakodnevnog &#x017E;ivota bolesnika, pobolj&#x0161;anje motori&#x010D;kih deficita, ravnote&#x017E;e, brzine hoda te pove&#x0107;anje kvalitete &#x017E;ivota. (<xref ref-type="bibr" rid="r25"><italic>25</italic></xref>, <xref ref-type="bibr" rid="r26"><italic>26</italic></xref>) Tako&#x0111;er se povezuje u&#x010D;inak modaliteta fizikalne i rehabilitacijske medicine s poja&#x010D;anim u&#x010D;inkom levodope. (<xref ref-type="bibr" rid="r27"><italic>27</italic></xref>)</p>
<p>Ve&#x0107;ina oboljelih upu&#x0107;uje se na rehabilitaciju tek u kasnijim stadijima bolesti s razvijenom klini&#x010D;kom slikom smanjene pokretljivosti, smrzavanjem hoda i visokim rizikom od pada, &#x0161;to umanjuje u&#x010D;inkovitost rehabilitacijskih postupaka. Naime, u kasnijem stadiju bolesti rehabilitacija rezultira djelomi&#x010D;nim pobolj&#x0161;anjem funkcije, ali se ne sprje&#x010D;ava tjelesno o&#x0161;te&#x0107;enje ili invaliditet. Prema smjernicama NICE (engl. <italic>National Institute for Health and Care Excellence</italic>) preporu&#x010D;uje se upu&#x0107;ivanje bolesnika na rehabilitaciju rano u tijeku bolesti ili odmah nakon postavljanja dijagnoze, &#x010D;ime se provodi sekundarna prevencija te usporava progresija invaliditeta. (<xref ref-type="bibr" rid="r23"><italic>23</italic></xref>)</p>
<p>Pri prvom pregledu specijalista fizikalne i rehabilitacijske medicine utvr&#x0111;uje se fizikalni status, te&#x017E;ina invaliditeta i kvaliteta &#x017E;ivota te se definiraju temeljne mjere ishoda rehabilitacije, kao i individualizirani kratkoro&#x010D;ni i dugoro&#x010D;ni ciljevi u rehabilitaciji. (<xref ref-type="bibr" rid="r23"><italic>23</italic></xref>) Stupanj te&#x017E;ine PB-a odre&#x0111;uje se skalom Hoehn i Yahr. To je jednostavna skala koja procjenjuje progresiju simptoma od nultog stupnja (bez znakova bolesti) do petog stupnja (nepokretan bolesnik u invalidskim kolicima ili u krevetu). (<xref ref-type="bibr" rid="r14"><italic>14</italic></xref>) Temelji se na posturalnoj nestabilnosti te ne uklju&#x010D;uje druge motori&#x010D;ke ili nemotori&#x010D;ke simptome. Ipak, vi&#x0161;i stupnjevi bolesti po skali Hoehn i Yahr odli&#x010D;no koreliraju s drugim standardiziranim skalama za motori&#x010D;ke simptome, invaliditet i kvalitetu &#x017E;ivota. (<xref ref-type="bibr" rid="r28"><italic>28</italic></xref>)</p>
<p>Najop&#x0161;irniji test za mjerenje te&#x017E;ine i progresije PB-a jest Jedinstvena ocjenska skala za procjenu Parkinsonove bolesti (engl. <italic>Unified Parkinson&#x2019;s Disease Rating Scale</italic> &#x2013; UPDRS). UPDRS su razvili neurolozi 1987. godine radi pra&#x0107;enja odgovora na lijekove u PB-u. Danas se UPDRS koristi za bolesnike kojima je dijagnosticiran idiopatski oblik PB-a u bilo kojem stadiju prema skali Hoehn i Yahr. Sastoji se od &#x010D;etiri dijela (prvi dio procjenjuje nemotori&#x010D;ke simptome: razmi&#x0161;ljanje, pona&#x0161;anje i raspolo&#x017E;enje, drugi dio aktivnosti svakodnevnog &#x017E;ivota, tre&#x0107;i dio motori&#x010D;ke funkcije, &#x010D;etvrti dio komplikacije terapije). Prva tri dijela ocjenjuju se na bodovnoj skali od nula do &#x010D;etiri, dok se &#x010D;etvrti dio ocjenjuje s <italic>da</italic> ili <italic>ne</italic>. Ve&#x0107;i rezultati ukazuju na te&#x017E;u bolest. (<xref ref-type="bibr" rid="r29"><italic>29</italic></xref>)</p>
<p>UPDRS III dio je testa koji se koristi za mjerenje motori&#x010D;kih funkcija i razine invaliditeta. Tako&#x0111;er je najva&#x017E;nija mjera u pra&#x0107;enju u&#x010D;inka modaliteta fizikalne medicine u PB-u. S daljnjim razvojem bolesti motori&#x010D;ki se simptomi pogor&#x0161;avaju, a time i rezultati UPDRS III. Dugoro&#x010D;no pobolj&#x0161;ani rezultati UPDRS III nakon zavr&#x0161;ene fizikalne terapije glavni su pokazatelji pozitivnog modificiraju&#x0107;eg u&#x010D;inka na PB. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>)</p>
<p>Naj&#x010D;e&#x0161;&#x0107;e primjenjivani testovi ravnote&#x017E;e jesu Bergova skala ravnote&#x017E;e (engl. <italic>Berg Balance Scale</italic> &#x2013; BBS), test sustava za procjenu ravnote&#x017E;e (engl. <italic>Balance Evaluation Systems Test</italic> &#x2013; BESTest), njegova skra&#x0107;ena verzija (engl. <italic>Mini Balance Evaluation Systems Test</italic> &#x2013; MiniBESTest) te funkcijski test dosega (engl. <italic>Functional Reach</italic>). Hod se procjenjuje testom hoda na deset metara (engl. <italic>10m walk test</italic> &#x2013; 10MWT), &#x0161;estominutnim testom hoda (engl. <italic>six-min walk test</italic> &#x2013; 6MWT) kojim se procjenjuje i funkcionalni kapacitet, upitnikom o pojavi smrzavanja hoda (engl. <italic>Freezing of Gait Questionnaire</italic> &#x2013; FOGQ) te mjerenjem vremena potrebnog za ustajanje i kretanje (engl. <italic>Timed Up and Go</italic> &#x2013; TUG). (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>)</p>
<p>Upitnik o Parkinsonovoj bolesti (engl. <italic>The 39 item Parkinson&#x2019;s disease questionnaire</italic> &#x2013; PDQ-39) sastoji se od 39 pitanja, a ocjenjuje utjecaj bolesti na kvalitetu &#x017E;ivota. Upitnik je podijeljen u osam kategorija (pokretljivost, aktivnosti svakodnevnog &#x017E;ivota, emocionalno stanje, stigma, socijalna podr&#x0161;ka, kognitivni status, komunikacija, tjelesna nelagoda) iz kojih se ra&#x010D;una indeks PB-a. (<xref ref-type="bibr" rid="r31"><italic>31</italic></xref>)</p>
<p>Nakon ocjene funkcija i stupnja bolesti odre&#x0111;uje se multidisciplinarni plan rehabilitacije. Rehabilitaciju &#x010D;ine aktivni modaliteti fizikalne i rehabilitacijske medicine, radna terapija te terapija govora i gutanja. (<xref ref-type="bibr" rid="r26"><italic>26</italic></xref>, <xref ref-type="bibr" rid="r32"><italic>32</italic></xref>) Va&#x017E;ne su redovite kontrole specijalista fizikalne i rehabilitacijske medicine svakih &#x0161;est do dvanaest mjeseci kako bi se mogle br&#x017E;e uo&#x010D;iti manje promjene u statusu (npr. sporiji hod, gubitak ravnote&#x017E;e) na koje &#x0107;e biti usmjerena rehabilitacija (pove&#x0107;anje brzine hoda, smanjenje rizika od pada). (<xref ref-type="bibr" rid="r23"><italic>23</italic></xref>)</p>
</sec>
<sec>
<title>Fizikalna terapija</title>
<p>Povezanost vje&#x017E;banja i PB-a prvi put je opisana 1992. godine kada je uo&#x010D;eno da vje&#x017E;banje u odrasloj dobi zna&#x010D;ajno smanjuje rizik od nastanka PB-a tijekom &#x017E;ivota. (<xref ref-type="bibr" rid="r33"><italic>33</italic></xref>) Od tada su opisani razli&#x010D;iti aktivni modaliteti fizikalne terapije koji smanjuju motori&#x010D;ke i nemotori&#x010D;ke simptome bolesti. (<xref ref-type="bibr" rid="r34"><italic>34</italic></xref>, <xref ref-type="bibr" rid="r35"><italic>35</italic></xref>)</p>
<p>Pozitivni u&#x010D;inak koji je odr&#x017E;an nakon provo&#x0111;enja terapije ukazuje na povezanost izme&#x0111;u medicinskih vje&#x017E;bi i neuroplasti&#x010D;nosti mozga. U istra&#x017E;ivanjima na &#x017E;ivotinjama s induciranom PB nakon vje&#x017E;banja pove&#x0107;ala se ekspresija protuupalnih citokina, smanjila se razina proupalnih citokina, pove&#x0107;ala se razina neurotrofnih &#x010D;imbenika poput mo&#x017E;danog neurotrofnog &#x010D;imbenika (engl. <italic>brain-derived neurotrophic factor</italic> &#x2013; BDNF), usporio se gubitak dopaminergi&#x010D;nih neurona zahvaljuju&#x0107;i pove&#x0107;anoj ekspresiji tirozin hidroksilaze i dopaminskog transportera te je zamije&#x0107;ena pove&#x0107;ana ekspresija mitohondrijskih proteina i smanjena akumulacija &#x03B1;-sinukleina, &#x0161;to korelira s motori&#x010D;kim deficitom u PB-u. (<xref ref-type="bibr" rid="r36"><italic>36</italic></xref>, <xref ref-type="bibr" rid="r37"><italic>37</italic></xref>)</p>
<p>U osoba oboljelih od PB-a potvr&#x0111;en je u&#x010D;inak fizikalne terapije na neuroplasti&#x010D;nost mozga. Aerobne vje&#x017E;be visokog intenziteta na pokretnoj traci dovode do promjene kortikomotorne ekscitabilnosti transkranijskom magnetskom stimulacijom. Zabilje&#x017E;eno je produljenje kortikalnoga tihog perioda, tj. smanjenje kortikomotorne ekscitabilnosti koje je koreliralo s pobolj&#x0161;anjem motori&#x010D;kih funkcija i parametara hoda u PB-u. (<xref ref-type="bibr" rid="r38"><italic>38</italic></xref>) Tako&#x0111;er, pove&#x0107;avaju potencijal vezanja dopamina na dopaminske D2-receptore u strijatumu u ranom stadiju bolesti. (<xref ref-type="bibr" rid="r39"><italic>39</italic></xref>) Povi&#x0161;ene serumske koncentracije BDNF-a izmjerene su desetoga dana intenzivnoga aerobnog vje&#x017E;banja u oboljelih te je odr&#x017E;ana povi&#x0161;ena koncentracija kroz sljede&#x0107;a &#x010D;etiri tjedna trajanja terapije. BDNF ima neuroprotektivni u&#x010D;inak koji se prezentirao pove&#x0107;anim vezanjem dopamina za dopaminske transportere. (<xref ref-type="bibr" rid="r40"><italic>40</italic></xref>) Tako&#x0111;er su na&#x0111;ene funkcijske promjene mo&#x017E;danih struktura povezanih s motori&#x010D;kim u&#x010D;enjem koje su korelirale s pobolj&#x0161;anjem motori&#x010D;kih funkcija nakon aerobnih vje&#x017E;bi. (<xref ref-type="bibr" rid="r41"><italic>41</italic></xref>)</p>
<p>Kineziterapija, kao aktivni modalitet fizikalne i rehabilitacijske medicine, za osobe oboljele od PB-a ima za cilj pobolj&#x0161;ati mi&#x0161;i&#x0107;nu snagu, aerobni kapacitet, ravnote&#x017E;u, hod i funkcionalnu pokretljivost pomo&#x0107;u razli&#x010D;itih vrsta medicinskih vje&#x017E;bi (<xref ref-type="table" rid="t1">Table 1</xref>). (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>)</p>
<table-wrap id="t1" position="float">
<label>Table 1</label><caption><title>Modalities of physical therapy in the rehabilitation of patients with Parkinson&#x2019;s disease at the Department of Physical and Rehabilitation Medicine with Rheumatology in the Clinical Hospital Dubrava</title>
</caption>
<table frame="hsides" rules="groups">
<col width="100%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">Multimodalna fizikalna terapija / Multimodal physical therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">&#x2022;&#x2002;Tri ili vi&#x0161;e modaliteta fizikalne terapije uklju&#x010D;uju&#x0107;i aerobne vje&#x017E;be, vje&#x017E;be s otporom, ravnote&#x017E;e, hoda i koordinacije / Three or more modalities of physical therapy including aerobic, resistance, balance, gait and coordination training</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">Vje&#x017E;be s progresivnim otporom / Progressive resistance training</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">&#x2022;&#x2002;Ergometar za ekscentri&#x010D;ni trening snage / Ergometer for eccentric strength training<break/>&#x2022;&#x2002;Sprava za koncentri&#x010D;ni trening snage / Machine for concentric strength training<break/>&#x2022;&#x2002;Funkcionalni trening snage / Functional strength training</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">Aerobne vje&#x017E;be izdr&#x017E;ljivosti / Aerobic endurance training</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">&#x2022;&#x2002;Vje&#x017E;be na sobnom biciklu / Stationary bicycle training<break/>&#x2022;&#x2002;Aerobni trening / Aerobic training</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">Vje&#x017E;be ravnote&#x017E;e / Balance training</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">&#x2022;&#x2002;Vje&#x017E;be na stabilometriji / Training on stabilometric platform<break/>&#x2022;&#x2002;Vje&#x017E;be ravnote&#x017E;e na tlu / Balance training on the ground<break/>&#x2022;&#x2002;Vje&#x017E;be strategije kretanja / Movement strategy training<break/>&#x2022;&#x2002;Program prevencije pada / Fall prevention programme</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">Vje&#x017E;be hodanja / Gait training</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">&#x2022;&#x2002;Vje&#x017E;be hoda po tlu / Overground training</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">Vje&#x017E;be uz pomo&#x0107; vanjskih znakova / Cueing strategies</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">&#x2022;&#x2002;Vje&#x017E;be hoda s vizualnim znakovima (linije ili oznake na tlu) / Gait training with visual cues (lines or markers on the ground)<break/>&#x2022;&#x2002;Vje&#x017E;be hoda s auditornim znakovima (glazba na unaprijed postavljenoj frekvenciji) / Gait training with rhythmic auditory cues (music at a preset frequency)<break/>&#x2022;&#x2002;Vje&#x017E;be hoda sa somatosenzornim znakovima (taktilni osjet) / Gait training with somatosensory cues (tactile sensation)</td>
</tr>
</tbody></table></table-wrap>
<p>Zamije&#x0107;eno je kako su osobe oboljele od PB-a manje fizi&#x010D;ki aktivne od zdrave populacije. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>) Ve&#x0107; u ranom stadiju bolesti (1. stadij po skali Hoehn i Yahr) oboljeli prohodaju zna&#x010D;ajno manji broj koraka dnevno od zdravih pojedinaca. (<xref ref-type="bibr" rid="r42"><italic>42</italic></xref>) Fizi&#x010D;ka neaktivnost negativno utje&#x010D;e na kardiorespiratorni kapacitet (izra&#x017E;en kao maksimalna potro&#x0161;nja kisika pri tjelesnoj aktivnosti, tj. VO<sub>2</sub> max) te funkcionalni kapacitet za fizi&#x010D;ku aktivnost (izra&#x017E;en &#x0161;estominutnim testom hoda). (<xref ref-type="bibr" rid="r43"><italic>43</italic></xref>, <xref ref-type="bibr" rid="r44"><italic>44</italic></xref>) Kardiorespiratorni kapacitet tako&#x0111;er ovisi o te&#x017E;ini same bolesti s obzirom da je jo&#x0161; uvijek o&#x010D;uvan u blagom obliku, a smanjen u umjereno te&#x0161;kom do te&#x0161;kom obliku PB-a. Aerobne vje&#x017E;be zna&#x010D;ajno pove&#x0107;avaju kardiorespiratorni kapacitet te funkcionalni kapacitet. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>) Aerobne vje&#x017E;be koje uklju&#x010D;uju neki oblik hodanja (npr. vje&#x017E;be na pokretnoj traci ili nordijsko hodanje) pove&#x0107;avaju brzinu hoda, duljinu koraka, stabilnost u hodu (smanjena varijabilnost hoda) i skra&#x0107;uju vrijeme oslonca na dvije noge u hodu. (<xref ref-type="bibr" rid="r35"><italic>35</italic></xref>, <xref ref-type="bibr" rid="r45"><italic>45</italic></xref>-<xref ref-type="bibr" rid="r47"><italic>47</italic></xref>) Pozitivan u&#x010D;inak aerobnih vje&#x017E;bi odr&#x017E;an je najmanje dvanaest tjedana. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>) Gubitak ostvarenog napretka nakon dvanaest tjedana povezan je s prestankom vje&#x017E;banja te bi se mogao o&#x010D;uvati kontinuiranom fizi&#x010D;kom aktivno&#x0161;&#x0107;u. (<xref ref-type="bibr" rid="r48"><italic>48</italic></xref>) Tako&#x0111;er, aerobne vje&#x017E;be smanjuju umor te pobolj&#x0161;avaju kognitivne funkcije, raspolo&#x017E;enje i kvalitetu &#x017E;ivota. (<xref ref-type="bibr" rid="r47"><italic>47</italic></xref>, <xref ref-type="bibr" rid="r49"><italic>49</italic></xref>)</p>
<p>Poznato je kako oboljeli od PB-a br&#x017E;e gube mi&#x0161;i&#x0107;nu snagu. Smanjena snaga uz hipokinezu i bradikinezu zatvara za&#x010D;arani krug smanjene pokretljivosti, &#x0161;to rezultira daljnjom atrofijom mi&#x0161;i&#x0107;a te smanjenjem amplitude i brzine pokreta. Vje&#x017E;be s otporom pove&#x0107;avaju mi&#x0161;i&#x0107;nu snagu te smanjuju bradikinezu. (<xref ref-type="bibr" rid="r50"><italic>50</italic></xref>) Biopsijom mi&#x0161;i&#x0107;a potvr&#x0111;ena je hipertrofija mi&#x0161;i&#x0107;nih vlakana nakon vje&#x017E;bi s otporom (<xref ref-type="bibr" rid="r51"><italic>51</italic></xref>), dok je elektromiografski (EMG) izmjerena smanjena segmentacija mi&#x0161;i&#x0107;nih kontrakcija i ve&#x0107;a aktivacija mi&#x0161;i&#x0107;a. (<xref ref-type="bibr" rid="r52"><italic>52</italic></xref>) Pove&#x0107;ana mi&#x0161;i&#x0107;na snaga pobolj&#x0161;ava posturalnu ravnote&#x017E;u i hod. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>) Tako&#x0111;er, vje&#x017E;be s otporom smanjuju motori&#x010D;ke simptome bolesti &#x010D;ak i u oboljelih koji nisu farmakolo&#x0161;ki lije&#x010D;eni. (<xref ref-type="bibr" rid="r53"><italic>53</italic></xref>) Pozitivan u&#x010D;inak vje&#x017E;bi s otporom na snagu mi&#x0161;i&#x0107;a, ravnote&#x017E;u i pokretljivost odr&#x017E;an je najmanje dvanaest tjedana nakon zavr&#x0161;ene fizikalne terapije. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>)</p>
<p>U oboljelih od PB-a poreme&#x0107;aj hoda je &#x010D;esta pojava. Karakteristi&#x010D;ni su sitni koraci, spori hod te produljeno vrijeme oslonca na dvije noge u hodu. (<xref ref-type="bibr" rid="r54"><italic>54</italic></xref>) Tako&#x0111;er je smanjena rotacija trupa i zdjelice pri hodu te je pove&#x0107;ana varijabilnost duljine koraka. (<xref ref-type="bibr" rid="r55"><italic>55</italic></xref>, <xref ref-type="bibr" rid="r56"><italic>56</italic></xref>) Hipokineti&#x010D;ki uzorak hodanja pridonosi pove&#x0107;anom broju pada u oboljelih. Vje&#x017E;be hoda zna&#x010D;ajno pobolj&#x0161;avaju brzinu hoda, duljinu koraka, omjer oslonca na jednoj i na dvije noge u hodu te kapacitet hodanja. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>) Vje&#x017E;be hoda na pokretnoj traci zna&#x010D;ajno pobolj&#x0161;avaju brzinu hoda, dok nordijsko hodanje uz pobolj&#x0161;anje funkcionalnog kapaciteta ima i pozitivni u&#x010D;inak na ravnote&#x017E;u. (<xref ref-type="bibr" rid="r35"><italic>35</italic></xref>) Vje&#x017E;be hoda smanjuju i nemotori&#x010D;ke simptome poput depresije. (<xref ref-type="bibr" rid="r57"><italic>57</italic></xref>) Kori&#x0161;tenje auditornih znakova u hodanju pove&#x0107;ava brzinu hoda i duljinu koraka (<xref ref-type="bibr" rid="r58"><italic>58</italic></xref>), a vizualni znakovi poput nazna&#x010D;enih linija na pokretnoj traci smanjuju pojavnost smrzavanja hoda (<xref ref-type="bibr" rid="r59"><italic>59</italic></xref>). Pozitivan u&#x010D;inak vje&#x017E;bi na parametre hoda o&#x010D;uvan je do &#x0161;est mjeseci nakon zavr&#x0161;etka terapije. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>)</p>
<p>Posturalna nestabilnost javlja se u PB-u u stadiju 1,5&#x2013;2 prema skali Hoehn i Yahr. (<xref ref-type="bibr" rid="r60"><italic>60</italic></xref>) Specifi&#x010D;ni poreme&#x0107;aji ravnote&#x017E;e jesu zano&#x0161;enje pri stajanju na mjestu, nestabilnost u hodu, sporo okretanje, smanjena rotacija trupa, sni&#x017E;ena granica ravnote&#x017E;e (smanjena mogu&#x0107;nost odr&#x017E;avanja ravnote&#x017E;e u nagnutom polo&#x017E;aju), poreme&#x0107;ena anticipatorna posturalna prilagodba te smanjeni reakcijski posturalni odgovori. (<xref ref-type="bibr" rid="r54"><italic>54</italic></xref>, <xref ref-type="bibr" rid="r61"><italic>61</italic></xref>-<xref ref-type="bibr" rid="r63"><italic>63</italic></xref>) Smanjena brzina i amplituda posturalne prilagodbe utje&#x010D;e na smanjenu stabilnost tijekom zapo&#x010D;injanja hoda, dosezanja predmeta i transfera iz sjede&#x0107;eg u stoje&#x0107;i polo&#x017E;aj (<xref ref-type="bibr" rid="r64"><italic>64</italic></xref>, <xref ref-type="bibr" rid="r65"><italic>65</italic></xref>), dok poreme&#x0107;eni reakcijski posturalni odgovori pridonose pove&#x0107;anom riziku od pada. (<xref ref-type="bibr" rid="r66"><italic>66</italic></xref>) Rizik od pada je najve&#x0107;i u umjereno te&#x0161;kom stadiju bolesti (3. stadij prema skali Hoehn i Yahr). Daljnjom progresijom bolesti smanjuje se incidencija pada radi smanjene pokretljivosti i sedentarnog na&#x010D;ina &#x017E;ivota. (<xref ref-type="bibr" rid="r67"><italic>67</italic></xref>) Posljedice pada su prijelomi, imobilizacija, pove&#x0107;ani rizik od smje&#x0161;tanja u stacionarnu ustanovu i visoka smrtnost. (<xref ref-type="bibr" rid="r68"><italic>68</italic></xref>) Najpouzdaniji &#x010D;imbenik rizika pada su dva ili vi&#x0161;e slu&#x010D;ajeva pada u zadnjih godinu dana. (<xref ref-type="bibr" rid="r69"><italic>69</italic></xref>) Ostali nepromjenjivi &#x010D;imbenici rizika pada jesu te&#x017E;i oblik bolesti, dugo trajanje bolesti te visoke doze levodope. &#x010C;imbenici rizika pada na koje se mo&#x017E;e utjecati jesu smanjena snaga donjih ekstremiteta, poreme&#x0107;aj ravnote&#x017E;e, poreme&#x0107;aji hoda te smrzavanje hoda. (<xref ref-type="bibr" rid="r70"><italic>70</italic></xref>-<xref ref-type="bibr" rid="r72"><italic>72</italic></xref>) Vje&#x017E;be ravnote&#x017E;e zna&#x010D;ajno pobolj&#x0161;avaju ravnote&#x017E;u, hod i motori&#x010D;ke funkcije. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>, <xref ref-type="bibr" rid="r35"><italic>35</italic></xref>) Pozitivni u&#x010D;inak je o&#x010D;uvan dvanaest mjeseci. To je najdugotrajniji zabilje&#x017E;eni u&#x010D;inak modaliteta fizikalne terapije u PB-u. Pobolj&#x0161;ana ravnote&#x017E;a, hod i motori&#x010D;ke funkcije smanjuju u&#x010D;estalost pada. Zna&#x010D;ajno se smanjuje stopa pada odmah nakon zavr&#x0161;etka vje&#x017E;bi (&#x2013;37%), nakon tri mjeseca (&#x2013;81%) te nakon dvanaest mjeseci (&#x2013;62%). (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>) Ipak, primije&#x0107;en je pove&#x0107;ani rizik od pada u oboljelih s te&#x0161;kim motori&#x010D;kim deficitom (UPDRS III, rezultat &#x2265;27) nakon vje&#x017E;bi ravnote&#x017E;e. Mogu&#x0107;e je obja&#x0161;njenje kako zbog pove&#x0107;ane pokretljivosti i subjektivnog osje&#x0107;aja ravnote&#x017E;e nakon provedenih vje&#x017E;bi osobe oboljele od PB-a &#x010D;e&#x0161;&#x0107;e dolaze u izazovne situacije za koje bi trebale imati bolju ravnote&#x017E;u. Uz to, u uznapredovanim stadijima bolesti bolesnici imaju slabiji kognitivni status te nerazvijene strategije prevencije pada. (<xref ref-type="bibr" rid="r23"><italic>23</italic></xref>) Nadalje je primije&#x0107;ena i rje&#x0111;a pojavnost smrzavanja hoda nakon vje&#x017E;bi ravnote&#x017E;e. (<xref ref-type="bibr" rid="r73"><italic>73</italic></xref>) Uz navedene motori&#x010D;ke simptome, smanjuje se anksioznost, apatija, depresija te se pove&#x0107;ava kvaliteta &#x017E;ivota. (<xref ref-type="bibr" rid="r23"><italic>23</italic></xref>)</p>
<p>Smrzavanje hoda je kratkotrajna nemogu&#x0107;nost izvr&#x0161;avanja pokreta uz subjektivni osje&#x0107;aj nogu zalijepljenih za tlo u kasnijoj fazi bolesti. Javlja se pri zapo&#x010D;injanju hodanja, okretanju, hodanju po uskoj stazi te pri izvo&#x0111;enju druge radnje usporedno s hodanjem. (<xref ref-type="bibr" rid="r74"><italic>74</italic></xref>) Vje&#x017E;be s vanjskim znakovima temelje se na vizualnim, auditivnim ili taktilnim znakovima koji poma&#x017E;u zapo&#x010D;injanju i/ili kontinuitetu pokreta te smanjuju pojavu smrzavanja hoda. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>) Pomo&#x0107;u PET-a snimljena je pove&#x0107;ana metaboli&#x010D;ka aktivnost u desnim parijetalnim i temporalnim re&#x017E;njevima mozga te desnoj polutki malog mozga tijekom vje&#x017E;bi hoda s auditornim znakovima. Kako ta podru&#x010D;ja S&#x017D;S-a sudjeluju u senzomotornom procesuiranju, smatra se kako vanjski senzori&#x010D;ki znakovi pozitivno utje&#x010D;u na motori&#x010D;ke izvedbe. (<xref ref-type="bibr" rid="r75"><italic>75</italic></xref>) Vje&#x017E;be s vanjskim znakovima pobolj&#x0161;avaju parametre hoda, posebno brzinu hoda, motori&#x010D;ke funkcije i ravnote&#x017E;u. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>, <xref ref-type="bibr" rid="r35"><italic>35</italic></xref>) Iako imaju zna&#x010D;ajan pozitivni u&#x010D;inak tijekom vje&#x017E;banja, nije zamije&#x0107;en dugoro&#x010D;ni u&#x010D;inak nakon zavr&#x0161;ene terapije. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>)</p>
<p>Osim navedenih zasebnih modaliteta kineziterapije, mo&#x017E;e se provoditi vi&#x0161;e razli&#x010D;itih modaliteta terapije zajedno. Multimodalni pristup ima pozitivan u&#x010D;inak na motori&#x010D;ke funkcije, aktivnosti svakodnevnog &#x017E;ivota (rezultati UPDRS II) i samu te&#x017E;inu PB-a (ukupni rezultati UPDRS). (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>) U <italic>de novo</italic> dijagnosticiranoj PB nakon multimodalne terapije smanjena je terapijska doza levodope te su o&#x010D;uvani rezultati UPDRS II i III do dvije godine nakon terapije. (<xref ref-type="bibr" rid="r76"><italic>76</italic></xref>) Usporedbom multimodalne terapije i standardne fizikalne terapije, multimodalna terapija ima zna&#x010D;ajno bolje rezultate motori&#x010D;kih funkcija, ravnote&#x017E;e, aktivnosti svakodnevnog &#x017E;ivota te kvalitete &#x017E;ivota odmah po zavr&#x0161;etku terapije. Razlika izme&#x0111;u multimodalne i standardne terapije dalje se pove&#x0107;ava godinu dana nakon zavr&#x0161;etka terapija kada su rezultati standardne terapije smanjeni, a multimodalne terapije jo&#x0161; uvijek odr&#x017E;ani. (<xref ref-type="bibr" rid="r26"><italic>26</italic></xref>)</p>
<p>Uz navedene modalitete, oboljelima se preporu&#x010D;uju komplementarne metode poput borila&#x010D;kih vje&#x0161;tina, joge i plesa za pobolj&#x0161;anje motori&#x010D;kih i nemotori&#x010D;kih simptoma PB-a. <italic>Tai chi</italic> uklju&#x010D;uje ritmi&#x010D;ko prebacivanje te&#x017E;ine tijela, kontrolirane kretnje do granica stabilnosti, kora&#x010D;anje i okretanje, &#x0161;to mo&#x017E;e pridonijeti pobolj&#x0161;anju ravnote&#x017E;e i hoda. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>) Vje&#x017E;banje <italic>tai chija</italic> ima pozitivne u&#x010D;inke na ravnote&#x017E;u, brzinu hoda, duljinu koraka, pokretljivost te rezultate UPDRS III u oboljelih od PB-a. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>, <xref ref-type="bibr" rid="r35"><italic>35</italic></xref>, <xref ref-type="bibr" rid="r77"><italic>77</italic></xref>) Primije&#x0107;ena je smanjena u&#x010D;estalost pada tijekom vje&#x017E;banja do &#x0161;est mjeseci nakon zavr&#x0161;etka treninga. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>) Osim pobolj&#x0161;anja motori&#x010D;kih simptoma, <italic>tai chi</italic> ima pozitivan u&#x010D;inak na depresiju te pobolj&#x0161;anje kvalitete &#x017E;ivota. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>, <xref ref-type="bibr" rid="r77"><italic>77</italic></xref>)</p>
<p>Dok se <italic>tai chi</italic> temelji na stajanju i dinami&#x010D;kim pokretima, u jogi je stavljen naglasak na meditaciju uma i tijela u sjede&#x0107;em i le&#x017E;e&#x0107;em polo&#x017E;aju. (<xref ref-type="bibr" rid="r77"><italic>77</italic></xref>) Vje&#x017E;banje joge pobolj&#x0161;ava pokretljivost, smanjuje motori&#x010D;ke simptome te ima pozitivan u&#x010D;inak na depresiju i anksioznost. Uz smanjenje anksioznosti i depresije tijekom vje&#x017E;banja, joga poma&#x017E;e u smanjenju anksioznosti u budu&#x0107;im situacijama. Druge komplementarne metode poput borila&#x010D;kih vje&#x0161;tina i plesa pozitivno utje&#x010D;u na psihi&#x010D;ke tegobe, ali njihovi pozitivni u&#x010D;inci se br&#x017E;e gube u fazi pra&#x0107;enja bolesnika nakon zavr&#x0161;etka treninga. (<xref ref-type="bibr" rid="r78"><italic>78</italic></xref>)</p>
<p>Ples je popularna komplementarna metoda u PB-u za pobolj&#x0161;anje motori&#x010D;kih simptoma. Ritam glazbe mo&#x017E;e poslu&#x017E;iti kao vanjski znak za po&#x010D;etak ili nastavak pokreta, a ponavljanje kretnji, kora&#x010D;anje i okretanje mo&#x017E;e pobolj&#x0161;ati ravnote&#x017E;u, pokretljivost i smanjiti motori&#x010D;ke simptome. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>, <xref ref-type="bibr" rid="r35"><italic>35</italic></xref>) Tango je naj&#x010D;e&#x0161;&#x0107;i plesni stil izbora u PB-u. U usporedbi s plesanjem valcera, tango ima zna&#x010D;ajnije pobolj&#x0161;anje ravnote&#x017E;e i kapaciteta hodanja. U oboljelih koji su plesali dulje vrijeme (&#x0161;est do dvanaest mjeseci) zamije&#x0107;ena je smanjena pojava smrzavanja hoda te pobolj&#x0161;ani rezultati UPDRS III. Tako&#x0111;er, plesanje pobolj&#x0161;ava kvalitetu &#x017E;ivota. Grupni te&#x010D;ajevi plesa ili borila&#x010D;kih vje&#x0161;tina koji uklju&#x010D;uju interakciju oboljelih mogu pove&#x0107;ati motivaciju za vje&#x017E;banjem. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>)</p>
<p>Tijekom multimodalne terapije, vje&#x017E;bi s otporom, vje&#x017E;bi ravnote&#x017E;e, vje&#x017E;bi hoda, nordijskog hodanja, <italic>tai chija</italic> i plesa prijavljene su ozljede malog broja oboljelih. Naj&#x010D;e&#x0161;&#x0107;a ozljeda tijekom vje&#x017E;banja jest pad bez prijeloma. Drugi &#x0161;tetni u&#x010D;inci vje&#x017E;banja jesu bol u zglobovima i mi&#x0161;i&#x0107;ima, hipotenzija, vrtoglavica i umor. Rizik od ozlje&#x0111;ivanja tijekom fizikalne terapije je nizak te se vje&#x017E;banje smatra sigurnim za osobe oboljele od PB-a. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>)</p>
</sec>
<sec>
<title>Radna terapija</title>
<p>S progresijom bolesti motori&#x010D;ki poreme&#x0107;aji negativno utje&#x010D;u na izvr&#x0161;avanje svakodnevnih aktivnosti. Radna terapija temelji se na oporavku i prilagodbi radnji potrebnih za obavljanje profesionalnih, rekreacijskih i svakodnevnih aktivnosti. Funkcijski zadatci uklju&#x010D;uju brigu o sebi, transfere te vo&#x0111;enje ku&#x0107;anstva. (<xref ref-type="bibr" rid="r79"><italic>79</italic></xref>) Bolje rezultate ima intenzivna radna terapija kra&#x0107;eg trajanja nego terapija umjerenijeg intenziteta i duljeg trajanja. (<xref ref-type="bibr" rid="r80"><italic>80</italic></xref>) Oboljeli od PB-a primje&#x0107;uju pobolj&#x0161;anje u izvo&#x0111;enju svakodnevnih aktivnosti nakon provedene radne terapije te pove&#x0107;anu samostalnost. (<xref ref-type="bibr" rid="r81"><italic>81</italic></xref>) Tako&#x0111;er se pobolj&#x0161;ava motori&#x010D;ka funkcija gornjih ekstremiteta. Radna terapija produljuje samostalnost u svakodnevnim aktivnostima. (<xref ref-type="bibr" rid="r80"><italic>80</italic></xref>)</p>
</sec>
<sec>
<title>Terapija govora</title>
<p>Velik udio oboljelih od PB-a razvije poreme&#x0107;aj govora uklju&#x010D;uju&#x0107;i promijenjene laringealne, respiratorne i artikulacijske funkcije. Promjene glasa uklju&#x010D;uju smanjenu glasno&#x0107;u (hipofonija), smanjenu varijabilnost visine glasa (monotoni glas), promuklost te nejasnu artikulaciju. Navedene se promjene glasa zajedni&#x010D;kim imenom zovu hipokineti&#x010D;ka dizartrija. Pojavljuju se rano u tijeku bolesti te uz smanjenu ekspresiju lica (lice poput maske) ograni&#x010D;avaju svakodnevnu komunikaciju, zbog &#x010D;ega oboljeli od PB-a rje&#x0111;e sudjeluju u razgovorima te se povla&#x010D;e iz dru&#x0161;tva. Terapija govora s logopedom jest metoda koja mo&#x017E;e popraviti govor. (<xref ref-type="bibr" rid="r82"><italic>82</italic></xref>) Koriste se razli&#x010D;ite tehnike koje se temelje na pobolj&#x0161;anju prozodije glasa (visine i tona glasa), artikulacije, glasno&#x0107;e glasa i fonacije te na pove&#x0107;anju aktivnosti respiratornih mi&#x0161;i&#x0107;a. (<xref ref-type="bibr" rid="r83"><italic>83</italic></xref>) Vokalna terapija Lee Silverman (LSVT) temelji se na jednostavnim zadatcima (poput proizvodnje samoglasnika, &#x010D;itanja odlomka, odr&#x017E;avanja monologa) koji zahtijevaju fonacijski i respiracijski trud. Cilj zadataka je pove&#x0107;anje glasno&#x0107;e glasa da bi se &#x201E;kalibrirao&#x201C; glas. LSVT pobolj&#x0161;ava mi&#x0161;i&#x0107;nu aktivnost i sinergiju laringealnih mi&#x0161;i&#x0107;a, adukciju glasnica te konfiguraciju vokalnog trakta. Posljedi&#x010D;no se popravlja kvaliteta i glasno&#x0107;a glasa, artikulacija, prozodija, zvu&#x010D;nost i razumljivost govora. Napredak govora nakon zavr&#x0161;etka terapije o&#x010D;uvan je do dvije godine. Pobolj&#x0161;anje usmene komunikacije ima velik utjecaj na kvalitetu &#x017E;ivota. (<xref ref-type="bibr" rid="r84"><italic>84</italic></xref>)</p>
<p>Uz terapiju govora, u kasnijoj fazi bolesti &#x010D;esto je potrebna terapija gutanja. Disfagija se u ranom stadiju bolesti mo&#x017E;e ubla&#x017E;iti uz pomo&#x0107; lijekova poput levodope koji pobolj&#x0161;avaju motoriku i brzinu gutanja. S napredovanjem bolesti disfagija postaje rezistentna na lijekove te je nu&#x017E;na terapija gutanja i promjena prehrane. Najbolji odgovor na terapiju ima bla&#x017E;i oblik orofaringealne disfagije. (<xref ref-type="bibr" rid="r85"><italic>85</italic></xref>)</p>
</sec>
</sec>
<sec sec-type="other6">
<title>Zaklju&#x010D;ak</title>
<p>Rehabilitacija predstavlja neizostavan dio lije&#x010D;enja oboljelih od PB-a. Te&#x017E;ina PB-a utje&#x010D;e na ishod terapije zbog &#x010D;ega su oboljeli u ranom stadiju ciljna populacija za modalitete fizikalne medicine, u prvom redu kineziterapiju. Odmah po postavljanju dijagnoze ili rano u tijeku bolesti bolesnici bi trebali biti upu&#x0107;eni na pregled specijalistu fizikalne i rehabilitacijske medicine koji &#x0107;e, u transdisciplinarnom timu s neurologom, definirati stupanj bolesti (skala Hoehn i Yahr), te&#x017E;inu bolesti (UPDRS), motori&#x010D;ke simptome i razinu invaliditeta (UPDRS III), ravnote&#x017E;u (BBS, BESTest, MiniBESTest, funkcijski test dosega), funkcionalni kapacitet (6MWT, 10MWT), parametre hoda (brzina hoda, duljina koraka), smrzavanje hoda (FOGQ), pokretljivost (TUG) te kvalitetu &#x017E;ivota (PDQ-8, PDQ-39). Nakon utvr&#x0111;ivanja inicijalnog stanja, donosi se individualizirani plan rehabilitacije s definiranim kratkoro&#x010D;nim i dugoro&#x010D;nim ciljevima rehabilitacije. Na redovitim kontrolnim pregledima specijalista fizikalne i rehabilitacijske medicine svakih &#x0161;est do dvanaest mjeseci prate se rehabilitacijski u&#x010D;inci te se uo&#x010D;avaju novonastale promjene u fizikalnom statusu, prema &#x010D;emu se korigira rehabilitacijski plan. Rehabilitacijski plan uklju&#x010D;uje razli&#x010D;ite modalitete fizikalne i rehabilitacijske medicine, a mo&#x017E;e uklju&#x010D;ivati i radnu terapiju te terapiju govora i gutanja. Ciljevi modaliteta fizikalne medicine jesu pobolj&#x0161;anje motori&#x010D;kih funkcija, mi&#x0161;i&#x0107;ne snage, aerobnog kapaciteta, hoda, ravnote&#x017E;e te kvalitete &#x017E;ivota. Aerobne vje&#x017E;be pove&#x0107;avaju kardiorespiratorni kapacitet i funkcionalni kapacitet. Vje&#x017E;be s otporom pove&#x0107;avaju mi&#x0161;i&#x0107;nu snagu te pobolj&#x0161;avaju ravnote&#x017E;u i pokretljivost. Vje&#x017E;be hoda imaju pozitivan u&#x010D;inak na razli&#x010D;ite parametre hoda poput brzine i duljine koraka te pove&#x0107;avaju kapacitet hodanja. Vje&#x017E;be ravnote&#x017E;e pobolj&#x0161;avaju ravnote&#x017E;u, hod, motori&#x010D;ke funkcije i smanjuju rizik od pada. Vje&#x017E;be s vanjskim znakovima smanjuju u&#x010D;estalost epizoda smrzavanja hoda te pobolj&#x0161;avaju hod i motori&#x010D;ke funkcije. <italic>Tai chi</italic>, joga i ples pobolj&#x0161;avaju motori&#x010D;ke funkcije, ravnote&#x017E;u, hod, smanjuju u&#x010D;estalost pada te smanjuju anksioznost i depresiju u oboljelih od PB-a. Multimodalna terapija ima pozitivne u&#x010D;inke na motori&#x010D;ke funkcije i smanjuje ukupni rezultat UPDRS, tj. te&#x017E;inu bolesti. Rezultati multimodalne terapije dulje su o&#x010D;uvani od rezultata standardne fizikalne terapije te se preporu&#x010D;uje rehabilitacija koja se sastoji od tri ili vi&#x0161;e razli&#x010D;itih modaliteta fizikalne terapije.</p>
<p>S obzirom na to da je PB kroni&#x010D;na progresivna bolest, va&#x017E;na je dugoro&#x010D;nost u&#x010D;inka terapije. Dugoro&#x010D;no pobolj&#x0161;anje tjelesnih funkcija nakon aktivnih modaliteta fizikalne i rehabilitacijske medicine u osoba s PB-om ukazuje na neuroplasti&#x010D;ne promjene u motori&#x010D;kim i kognitivnim mo&#x017E;danim spojevima ovisne o vje&#x017E;banju. Vje&#x017E;be hoda u trajanju od najmanje &#x010D;etiri tjedna te vje&#x017E;be ravnote&#x017E;e od najmanje osam tjedana imaju pozitivne u&#x010D;inke koji mogu trajati od tri do dvanaest mjeseci nakon zavr&#x0161;etka terapije. Vje&#x017E;be s otporom, aerobne vje&#x017E;be, <italic>tai chi</italic> i ples u trajanju od najmanje dvanaest tjedana imaju dugoro&#x010D;ne pozitivne u&#x010D;inke. <xref ref-type="fig" rid="f1">Figure 1</xref> prikazuje hodogram rehabilitacije bolesnika oboljelih od PB-a koji se primjenjuje u svakodnevnoj klini&#x010D;koj praksi u Zavodu za fizikalnu i rehabilitacijsku medicinu s reumatologijom Klini&#x010D;ke bolnice Dubrava. Potrebna su daljnja istra&#x017E;ivanja koja &#x0107;e pokazati povezanost u&#x010D;inkovitosti s intenzitetom i trajanjem pojedinog modaliteta fizikalne i rehabilitacijske medicine u bolesnika s PB-om.</p>
<fig id="f1" position="float" fig-type="figure"><label>Figure 1</label><caption><p>UPDRS = Jedinstvena skala za procjenu Parkinsonove bolesti / UPDRS = Unified Parkinson Disease Rating Scale; 6MWT = 6-minutni test hoda / 6MWT = 6-min walk test; 10MWT = Test hoda na 10 metara / 6MWT = 10 meters walk test; BBS = Bergova skala ravnote&#x017E;e / BBS = Berg Balance Scale; miniBEST = kratki test za procjenu sustava ravnote&#x017E;e / miniBEST = mini Balance Evaluation Systems&#x2019; Test; BEST = test za procjenu sustava ravnote&#x017E;e / BEST = Balance Evaluation Systems&#x2019; Test; TUG = vrijeme potrebno za ustajanje i kretanje / TUG = Timed Up and Go; PDQ = Upitnik o kvaliteti &#x017E;ivota s Parkinsonovom bolesti / PDQ = Parkinson&#x2019;s Disease Questionnaire; FRM = fizikalna i rehabilitacijska medicina / PRM = physical and rehabilitation medicine</p></caption><graphic xlink:href="LV-145-297-f1"></graphic></fig>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<p content-type="fn-title">INFORMACIJE O SUKOBU INTERESA</p>
<p>Autori nisu deklarirali sukob interesa relevantan za ovaj rad.</p>
</fn>
<fn fn-type="financial-disclosure">
<p content-type="fn-title">INFORMACIJA O FINANCIRANJU</p>
<p>Za ovaj &#x010D;lanak nisu primljena financijska sredstva.</p>
</fn>
</fn-group>
<ref-list>
<title>LITERATURA</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="book">Parkinson J. An Essay on the Shaking Palsy. London: Sherwood, Neely and Jones; 1817.</mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name><name><surname>Tanner</surname><given-names>CM</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><name><surname>Brundin</surname><given-names>P</given-names></name><name><surname>Volkmann</surname><given-names>J</given-names></name><etal/></person-group> <article-title>Parkinson disease.</article-title> <source>Nat Rev Dis Primers</source>. <year>2017</year>;<volume>3</volume>:<fpage>17013</fpage>. <pub-id pub-id-type="doi">10.1038/nrdp.2017.13</pub-id><pub-id pub-id-type="pmid">28332488</pub-id></mixed-citation></ref>
<ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pringsheim</surname><given-names>T</given-names></name><name><surname>Jette</surname><given-names>N</given-names></name><name><surname>Frolkis</surname><given-names>A</given-names></name><name><surname>Steeves</surname><given-names>TD</given-names></name></person-group>. <article-title>The prevalence of Parkinson&#x2019;s disease: a systematic review and meta-analysis.</article-title> <source>Mov Disord</source>. <year>2014</year>;<volume>29</volume>(<issue>13</issue>):<fpage>1583</fpage>&#x2013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1002/mds.25945</pub-id><pub-id pub-id-type="pmid">24976103</pub-id></mixed-citation></ref>
<ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shulman</surname><given-names>LM</given-names></name></person-group>. <article-title>Gender differences in Parkinson&#x2019;s disease.</article-title> <source>Gend Med</source>. <year>2007</year>;<volume>4</volume>(<issue>1</issue>):<fpage>8</fpage>&#x2013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/S1550-8579(07)80003-9</pub-id><pub-id pub-id-type="pmid">17584622</pub-id></mixed-citation></ref>
<ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noyce</surname><given-names>AJ</given-names></name><name><surname>Bestwick</surname><given-names>JP</given-names></name><name><surname>Silveira-Moriyama</surname><given-names>L</given-names></name><name><surname>Hawkes</surname><given-names>CH</given-names></name><name><surname>Giovannoni</surname><given-names>G</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><etal/></person-group> <article-title>Meta-analysis of early nonmotor features and risk factors for Parkinson disease.</article-title> <source>Ann Neurol</source>. <year>2012</year>;<volume>72</volume>:<fpage>893</fpage>&#x2013;<lpage>901</lpage>. <pub-id pub-id-type="doi">10.1002/ana.23687</pub-id><pub-id pub-id-type="pmid">23071076</pub-id></mixed-citation></ref>
<ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ascherio</surname><given-names>A</given-names></name><name><surname>Schwarzschild</surname><given-names>MA</given-names></name></person-group>. <article-title>The epidemiology of Parkinson&#x2019;s disease: risk factors and prevention.</article-title> <source>Lancet Neurol</source>. <year>2016</year>;<volume>15</volume>(<issue>12</issue>):<fpage>1257</fpage>&#x2013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(16)30230-7</pub-id><pub-id pub-id-type="pmid">27751556</pub-id></mixed-citation></ref>
<ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corti</surname><given-names>O</given-names></name><name><surname>Lesage</surname><given-names>S</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name></person-group>. <article-title>What genetics tells us about the causes and mechanisms of Parkinson&#x2019;s disease.</article-title> <source>Physiol Rev</source>. <year>2011</year>;<volume>91</volume>(<issue>4</issue>):<fpage>1161</fpage>&#x2013;<lpage>218</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00022.2010</pub-id><pub-id pub-id-type="pmid">22013209</pub-id></mixed-citation></ref>
<ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polymeropoulos</surname><given-names>MH</given-names></name><name><surname>Higgins</surname><given-names>JJ</given-names></name><name><surname>Golbe</surname><given-names>LI</given-names></name><name><surname>Johnson</surname><given-names>WG</given-names></name><name><surname>Ide</surname><given-names>SE</given-names></name><name><surname>Di Iorio</surname><given-names>G</given-names></name><etal/></person-group> <article-title>Mapping of a gene for Parkinson&#x2019;s disease to chromosome 4q21-q23.</article-title> <source>Science</source>. <year>1996</year>;<volume>274</volume>(<issue>5290</issue>):<fpage>1197</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1126/science.274.5290.1197</pub-id><pub-id pub-id-type="pmid">8895469</pub-id></mixed-citation></ref>
<ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polymeropoulos</surname><given-names>MH</given-names></name><name><surname>Lavedan</surname><given-names>C</given-names></name><name><surname>Leroy</surname><given-names>E</given-names></name><name><surname>Ide</surname><given-names>SE</given-names></name><name><surname>Dehejia</surname><given-names>A</given-names></name><name><surname>Dutra</surname><given-names>A</given-names></name><etal/></person-group> <article-title>Mutation in the alpha-synuclein gene identified in families with Parkinson&#x2019;s disease.</article-title> <source>Science</source>. <year>1997</year>;<volume>276</volume>(<issue>5321</issue>):<fpage>2045</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1126/science.276.5321.2045</pub-id><pub-id pub-id-type="pmid">9197268</pub-id></mixed-citation></ref>
<ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacMahon Copas</surname><given-names>AN</given-names></name><name><surname>McComish</surname><given-names>SF</given-names></name><name><surname>Fletcher</surname><given-names>JM</given-names></name><name><surname>Caldwell</surname><given-names>MA</given-names></name></person-group>. <article-title>The Pathogenesis of Parkinson&#x2019;s Disease: A Complex Interplay Between Astrocytes, Microglia, and T Lymphocytes?</article-title> <source>Front Neurol</source>. <year>2021</year>;<volume>12</volume>:<elocation-id>666737</elocation-id>. <pub-id pub-id-type="doi">10.3389/fneur.2021.666737</pub-id><pub-id pub-id-type="pmid">34122308</pub-id></mixed-citation></ref>
<ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fearnley</surname><given-names>JM</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name></person-group>. <article-title>Ageing and Parkinson&#x2019;s disease: substantia nigra regional selectivity.</article-title> <source>Brain</source>. <year>1991</year>;<volume>114</volume>(<issue>Pt 5</issue>):<fpage>2283</fpage>&#x2013;<lpage>301</lpage>. <pub-id pub-id-type="doi">10.1093/brain/114.5.2283</pub-id><pub-id pub-id-type="pmid">1933245</pub-id></mixed-citation></ref>
<ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwatsubo</surname><given-names>T</given-names></name></person-group>. <article-title>Aggregation of alpha-synuclein in the pathogenesis of Parkinson&#x2019;s disease.</article-title> <source>J Neurol</source>. <year>2003</year>;<volume>250</volume> <supplement>Suppl 3</supplement>:<fpage>III11</fpage>&#x2013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1007/s00415-003-1303-x</pub-id><pub-id pub-id-type="pmid">14579119</pub-id></mixed-citation></ref>
<ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Postuma</surname><given-names>RB</given-names></name><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Stern</surname><given-names>M</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>Olanow</surname><given-names>CW</given-names></name><name><surname>Oertel</surname><given-names>W</given-names></name><etal/></person-group> <article-title>MDS clinical diagnostic criteria for Parkinson&#x2019;s disease.</article-title> <source>Mov Disord</source>. <year>2015</year>;<volume>30</volume>(<issue>12</issue>):<fpage>1591</fpage>&#x2013;<lpage>601</lpage>. <pub-id pub-id-type="doi">10.1002/mds.26424</pub-id><pub-id pub-id-type="pmid">26474316</pub-id></mixed-citation></ref>
<ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jankovic</surname><given-names>J</given-names></name></person-group>. <article-title>Parkinson&#x2019;s disease: clinical features and diagnosis.</article-title> <source>J Neurol Neurosurg Psychiatry</source>. <year>2008</year>;<volume>79</volume>(<issue>4</issue>):<fpage>368</fpage>&#x2013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1136/jnnp.2007.131045</pub-id><pub-id pub-id-type="pmid">18344392</pub-id></mixed-citation></ref>
<ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Postuma</surname><given-names>RB</given-names></name><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Stern</surname><given-names>M</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>Olanow</surname><given-names>CW</given-names></name><name><surname>Oertel</surname><given-names>W</given-names></name><etal/></person-group> <article-title>MDS clinical diagnostic criteria for Parkinson&#x2019;s disease.</article-title> <source>Mov Disord</source>. <year>2015</year>;<volume>30</volume>(<issue>12</issue>):<fpage>1591</fpage>&#x2013;<lpage>601</lpage>. <pub-id pub-id-type="doi">10.1002/mds.26424</pub-id><pub-id pub-id-type="pmid">26474316</pub-id></mixed-citation></ref>
<ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name><name><surname>Tanner</surname><given-names>CM</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><name><surname>Brundin</surname><given-names>P</given-names></name><name><surname>Volkmann</surname><given-names>J</given-names></name><etal/></person-group> <article-title>Parkinson disease.</article-title> <source>Nat Rev Dis Primers</source>. <year>2017</year>;<volume>3</volume>:<fpage>17013</fpage>. <pub-id pub-id-type="doi">10.1038/nrdp.2017.13</pub-id><pub-id pub-id-type="pmid">28332488</pub-id></mixed-citation></ref>
<ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heim</surname><given-names>B</given-names></name><name><surname>Krismer</surname><given-names>F</given-names></name><name><surname>De Marzi</surname><given-names>R</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name></person-group>. <article-title>Magnetic resonance imaging for the diagnosis of Parkinson&#x2019;s disease.</article-title> <source>J Neural Transm (Vienna)</source>. <year>2017</year>;<volume>124</volume>(<issue>8</issue>):<fpage>915</fpage>&#x2013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1007/s00702-017-1717-8</pub-id><pub-id pub-id-type="pmid">28378231</pub-id></mixed-citation></ref>
<ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahlknecht</surname><given-names>P</given-names></name><name><surname>Hotter</surname><given-names>A</given-names></name><name><surname>Hussl</surname><given-names>A</given-names></name><name><surname>Esterhammer</surname><given-names>R</given-names></name><name><surname>Schocke</surname><given-names>M</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name></person-group>. <article-title>Significance of MRI in diagnosis and differential diagnosis of Parkinson&#x2019;s disease.</article-title> <source>Neurodegener Dis</source>. <year>2010</year>;<volume>7</volume>(<issue>5</issue>):<fpage>300</fpage>&#x2013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1159/000314495</pub-id><pub-id pub-id-type="pmid">20616565</pub-id></mixed-citation></ref>
<ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Politis</surname><given-names>M</given-names></name></person-group>. <article-title>Neuroimaging in Parkinson disease: from research setting to clinical practice.</article-title> <source>Nat Rev Neurol</source>. <year>2014</year>;<volume>10</volume>(<issue>12</issue>):<fpage>708</fpage>&#x2013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1038/nrneurol.2014.205</pub-id><pub-id pub-id-type="pmid">25385334</pub-id></mixed-citation></ref>
<ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen-Plotkin</surname><given-names>AS</given-names></name></person-group>. <article-title>Unbiased approaches to biomarker discovery in neurodegenerative diseases.</article-title> <source>Neuron</source>. <year>2014</year>;<volume>84</volume>(<issue>3</issue>):<fpage>594</fpage>&#x2013;<lpage>607</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2014.10.031</pub-id><pub-id pub-id-type="pmid">25442938</pub-id></mixed-citation></ref>
<ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coelho</surname><given-names>M</given-names></name><name><surname>Ferreira</surname><given-names>JJ</given-names></name></person-group>. <article-title>Late-stage Parkinson disease.</article-title> <source>Nat Rev Neurol</source>. <year>2012</year>;<volume>8</volume>(<issue>8</issue>):<fpage>435</fpage>&#x2013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1038/nrneurol.2012.126</pub-id><pub-id pub-id-type="pmid">22777251</pub-id></mixed-citation></ref>
<ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perestelo-P&#x00E9;rez</surname><given-names>L</given-names></name><name><surname>Rivero-Santana</surname><given-names>A</given-names></name><name><surname>P&#x00E9;rez-Ramos</surname><given-names>J</given-names></name><name><surname>Serrano-P&#x00E9;rez</surname><given-names>P</given-names></name><name><surname>Panetta</surname><given-names>J</given-names></name><name><surname>Hilarion</surname><given-names>P</given-names></name></person-group>. <article-title>Deep brain stimulation in Parkinson&#x2019;s disease: meta-analysis of randomized controlled trials.</article-title> <source>J Neurol</source>. <year>2014</year>;<volume>261</volume>(<issue>11</issue>):<fpage>2051</fpage>&#x2013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1007/s00415-014-7254-6</pub-id><pub-id pub-id-type="pmid">24487826</pub-id></mixed-citation></ref>
<ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>TD</given-names></name><name><surname>Col&#x00F3;n-Semenza</surname><given-names>C</given-names></name><name><surname>DeAngelis</surname><given-names>TR</given-names></name><name><surname>Thomas</surname><given-names>CA</given-names></name><name><surname>Hilaire</surname><given-names>MS</given-names></name><name><surname>Earhart</surname><given-names>GM</given-names></name><etal/></person-group> <article-title>Evidence for Early and Regular Physical Therapy and Exercise in Parkinson&#x2019;s Disease.</article-title> <source>Semin Neurol</source>. <year>2021</year>;<volume>41</volume>(<issue>2</issue>):<fpage>189</fpage>&#x2013;<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1055/s-0041-1725133</pub-id><pub-id pub-id-type="pmid">33742432</pub-id></mixed-citation></ref>
<ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubenis</surname><given-names>J</given-names></name></person-group>. <article-title>A rehabilitational approach to the management of Parkinson&#x2019;s disease.</article-title> <source>Parkinsonism Relat Disord</source>. <year>2007</year>;<volume>13</volume>:<fpage>S495</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/S1353-8020(08)70055-5</pub-id><pub-id pub-id-type="pmid">18267289</pub-id></mixed-citation></ref>
<ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>T</given-names></name><name><surname>de Goede</surname><given-names>CJ</given-names></name><name><surname>Feldman</surname><given-names>RG</given-names></name><name><surname>Wolters</surname><given-names>EC</given-names></name><name><surname>Kwakkel</surname><given-names>G</given-names></name><name><surname>Wagenaar</surname><given-names>RC</given-names></name></person-group>. <article-title>Efficacy of a physical therapy program in patients with Parkinson&#x2019;s disease: a randomized controlled trial.</article-title> <source>Arch Phys Med Rehabil</source>. <year>2005</year>;<volume>86</volume>(<issue>4</issue>):<fpage>626</fpage>&#x2013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.apmr.2004.08.008</pub-id><pub-id pub-id-type="pmid">15827910</pub-id></mixed-citation></ref>
<ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monticone</surname><given-names>M</given-names></name><name><surname>Ambrosini</surname><given-names>E</given-names></name><name><surname>Laurini</surname><given-names>A</given-names></name><name><surname>Rocca</surname><given-names>B</given-names></name><name><surname>Foti</surname><given-names>C</given-names></name></person-group>. <article-title>In-patient multidisciplinary rehabilitation for Parkinson&#x2019;s disease: A randomized controlled trial.</article-title> <source>Mov Disord</source>. <year>2015</year>;<volume>30</volume>(<issue>8</issue>):<fpage>1050</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/mds.26256</pub-id><pub-id pub-id-type="pmid">26095443</pub-id></mixed-citation></ref>
<ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muhlack</surname><given-names>S</given-names></name><name><surname>Welnic</surname><given-names>J</given-names></name><name><surname>Woitalla</surname><given-names>D</given-names></name><name><surname>M&#x00FC;ller</surname><given-names>T</given-names></name></person-group>. <article-title>Exercise improves efficacy of levodopa in patients with Parkinson&#x2019;s disease.</article-title> <source>Mov Disord</source>. <year>2007</year>;<volume>22</volume>(<issue>3</issue>):<fpage>427</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1002/mds.21346</pub-id><pub-id pub-id-type="pmid">17226855</pub-id></mixed-citation></ref>
<ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goetz</surname><given-names>CG</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>Rascol</surname><given-names>O</given-names></name><name><surname>Sampaio</surname><given-names>C</given-names></name><name><surname>Stebbins</surname><given-names>GT</given-names></name><name><surname>Counsell</surname><given-names>C</given-names></name><etal/></person-group> <article-title>Movement Disorder Society Task Force on Rating Scales for Parkinson&#x2019;s Disease. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations.</article-title> <source>Mov Disord</source>. <year>2004</year>;<volume>19</volume>(<issue>9</issue>):<fpage>1020</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/mds.20213</pub-id><pub-id pub-id-type="pmid">15372591</pub-id></mixed-citation></ref>
<ref id="r29"><label>29</label><mixed-citation publication-type="web">American Physical Therapy Association. Unified Parkinson&#x2019;s Disease Rating Scale (UPDRS), Movement Disorders Society (MDS) Modified Unified Parkinson&#x2019;s Disease Rating Scale (MDS-UPDRS) [Internet]. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/unified-parkinsons-disease-rating-scale-updrs-movement-disorders-society-mds-modified-unified-parkinsons-disease-rating-scale-mds-updrs">https://www.apta.org/patient-care/evidence-based-practice-resources/test-measures/unified-parkinsons-disease-rating-scale-updrs-movement-disorders-society-mds-modified-unified-parkinsons-disease-rating-scale-mds-updrs</ext-link>. [Pristupljeno 14. 10. 2022.]</mixed-citation></ref>
<ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mak</surname><given-names>MK</given-names></name><name><surname>Wong-Yu</surname><given-names>IS</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Chung</surname><given-names>CL</given-names></name></person-group>. <article-title>Long-term effects of exercise and physical therapy in people with Parkinson disease.</article-title> <source>Nat Rev Neurol</source>. <year>2017</year>;<volume>13</volume>(<issue>11</issue>):<fpage>689</fpage>&#x2013;<lpage>703</lpage>. <pub-id pub-id-type="doi">10.1038/nrneurol.2017.128</pub-id><pub-id pub-id-type="pmid">29027544</pub-id></mixed-citation></ref>
<ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkinson</surname><given-names>C</given-names></name><name><surname>Fitzpatrick</surname><given-names>R</given-names></name><name><surname>Peto</surname><given-names>V</given-names></name><name><surname>Greenhall</surname><given-names>R</given-names></name><name><surname>Hyman</surname><given-names>N</given-names></name></person-group>. <article-title>The Parkinson&#x2019;s Disease Questionnaire (PDQ-39): development and validation of a Parkinson&#x2019;s disease summary index score.</article-title> <source>Age Ageing</source>. <year>1997</year>;<volume>26</volume>(<issue>5</issue>):<fpage>353</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1093/ageing/26.5.353</pub-id><pub-id pub-id-type="pmid">9351479</pub-id></mixed-citation></ref>
<ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olanow</surname><given-names>CW</given-names></name><name><surname>Stern</surname><given-names>MB</given-names></name><name><surname>Sethi</surname><given-names>K</given-names></name></person-group>. <article-title>The scientific and clinical basis for the treatment of Parkinson disease (2009).</article-title> <source>Neurology</source>. <year>2009</year>;<volume>72</volume>:<fpage>S1</fpage>&#x2013;<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0b013e3181a1d44c</pub-id><pub-id pub-id-type="pmid">19470958</pub-id></mixed-citation></ref>
<ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasco</surname><given-names>AJ</given-names></name><name><surname>Paffenbarger</surname><given-names>RS</given-names><suffix>Jr</suffix></name><name><surname>Gendre</surname><given-names>I</given-names></name><name><surname>Wing</surname><given-names>AL</given-names></name></person-group>. <article-title>The role of physical exercise in the occurrence of Parkinson&#x2019;s disease.</article-title> <source>Arch Neurol</source>. <year>1992</year>;<volume>49</volume>(<issue>4</issue>):<fpage>360</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1001/archneur.1992.00530280040020</pub-id><pub-id pub-id-type="pmid">1558515</pub-id></mixed-citation></ref>
<ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>YS</given-names></name><name><surname>Yang</surname><given-names>SD</given-names></name><name><surname>Tan</surname><given-names>ZX</given-names></name><name><surname>Wang</surname><given-names>MM</given-names></name><name><surname>Xing</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>F</given-names></name><etal/></person-group> <article-title>The benefits and mechanisms of exercise training for Parkinson&#x2019;s disease.</article-title> <source>Life Sci</source>. <year>2020</year>;<volume>245</volume>:<elocation-id>117345</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.lfs.2020.117345</pub-id><pub-id pub-id-type="pmid">31981631</pub-id></mixed-citation></ref>
<ref id="r35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radder</surname><given-names>DLM</given-names></name><name><surname>L&#x00ED;gia Silva de Lima</surname><given-names>A</given-names></name><name><surname>Domingos</surname><given-names>J</given-names></name><name><surname>Keus</surname><given-names>SHJ</given-names></name><name><surname>van Nimwegen</surname><given-names>M</given-names></name><name><surname>Bloem</surname><given-names>BR</given-names></name><etal/></person-group> <article-title>Physiotherapy in Parkinson&#x2019;s Disease: A Meta-Analysis of Present Treatment Modalities.</article-title> <source>Neurorehabil Neural Repair</source>. <year>2020</year>;<volume>34</volume>(<issue>10</issue>):<fpage>871</fpage>&#x2013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1177/1545968320952799</pub-id><pub-id pub-id-type="pmid">32917125</pub-id></mixed-citation></ref>
<ref id="r36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svensson</surname><given-names>M</given-names></name><name><surname>Lexell</surname><given-names>J</given-names></name><name><surname>Deierborg</surname><given-names>T</given-names></name></person-group>. <article-title>Effects of Physical Exercise on Neuroinflammation, Neuroplasticity, Neurodegeneration, and Behavior: What We Can Learn From Animal Models in Clinical Settings.</article-title> <source>Neurorehabil Neural Repair</source>. <year>2015</year>;<volume>29</volume>(<issue>6</issue>):<fpage>577</fpage>&#x2013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1177/1545968314562108</pub-id><pub-id pub-id-type="pmid">25527485</pub-id></mixed-citation></ref>
<ref id="r37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koo</surname><given-names>JH</given-names></name><name><surname>Cho</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>UB</given-names></name></person-group>. <article-title>Treadmill exercise alleviates motor deficits and improves mitochondrial import machinery in an MPTP-induced mouse model of Parkinson&#x2019;s disease.</article-title> <source>Exp Gerontol</source>. <year>2017</year>;<volume>89</volume>:<fpage>20</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.exger.2017.01.001</pub-id><pub-id pub-id-type="pmid">28062370</pub-id></mixed-citation></ref>
<ref id="r38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>BE</given-names></name><name><surname>Wu</surname><given-names>AD</given-names></name><name><surname>Salem</surname><given-names>GJ</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Yip</surname><given-names>J</given-names></name><etal/></person-group> <article-title>The effect of exercise training in improving motor performance and corticomotor excitability in people with early Parkinson&#x2019;s disease.</article-title> <source>Arch Phys Med Rehabil</source>. <year>2008</year>;<volume>89</volume>(<issue>7</issue>):<fpage>1221</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.apmr.2008.01.013</pub-id><pub-id pub-id-type="pmid">18534554</pub-id></mixed-citation></ref>
<ref id="r39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>BE</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Nacca</surname><given-names>A</given-names></name><name><surname>Salem</surname><given-names>GJ</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Yip</surname><given-names>J</given-names></name><etal/></person-group> <article-title>Treadmill exercise elevates striatal dopamine D2 receptor binding potential in patients with early Parkinson&#x2019;s disease.</article-title> <source>Neuroreport</source>. <year>2013</year>;<volume>24</volume>(<issue>10</issue>):<fpage>509</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1097/WNR.0b013e328361dc13</pub-id><pub-id pub-id-type="pmid">23636255</pub-id></mixed-citation></ref>
<ref id="r40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frazzitta</surname><given-names>G</given-names></name><name><surname>Maestri</surname><given-names>R</given-names></name><name><surname>Ghilardi</surname><given-names>MF</given-names></name><name><surname>Riboldazzi</surname><given-names>G</given-names></name><name><surname>Perini</surname><given-names>M</given-names></name><name><surname>Bertotti</surname><given-names>G</given-names></name><etal/></person-group> <article-title>Intensive rehabilitation increases BDNF serum levels in parkinsonian patients: a randomized study.</article-title> <source>Neurorehabil Neural Repair</source>. <year>2014</year>;<volume>28</volume>(<issue>2</issue>):<fpage>163</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1177/1545968313508474</pub-id><pub-id pub-id-type="pmid">24213955</pub-id></mixed-citation></ref>
<ref id="r41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duchesne</surname><given-names>C</given-names></name><name><surname>Gheysen</surname><given-names>F</given-names></name><name><surname>Bore</surname><given-names>A</given-names></name><name><surname>Albouy</surname><given-names>G</given-names></name><name><surname>Nadeau</surname><given-names>A</given-names></name><name><surname>Robillard</surname><given-names>ME</given-names></name><etal/></person-group> <article-title>Influence of aerobic exercise training on the neural correlates of motor learning in Parkinson&#x2019;s disease individuals.</article-title> <source>Neuroimage Clin</source>. <year>2016</year>;<volume>12</volume>:<fpage>559</fpage>&#x2013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/j.nicl.2016.09.011</pub-id><pub-id pub-id-type="pmid">27689020</pub-id></mixed-citation></ref>
<ref id="r42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname><given-names>S</given-names></name><name><surname>Godfrey</surname><given-names>A</given-names></name><name><surname>Galna</surname><given-names>B</given-names></name><name><surname>Mhiripiri</surname><given-names>D</given-names></name><name><surname>Burn</surname><given-names>D</given-names></name><name><surname>Rochester</surname><given-names>L</given-names></name></person-group>. <article-title>Ambulatory activity in incident Parkinson&#x2019;s: more than meets the eye?</article-title> <source>J Neurol</source>. <year>2013</year>;<volume>260</volume>(<issue>12</issue>):<fpage>2964</fpage>&#x2013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1007/s00415-013-7037-5</pub-id><pub-id pub-id-type="pmid">23900754</pub-id></mixed-citation></ref>
<ref id="r43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canning</surname><given-names>CG</given-names></name><name><surname>Alison</surname><given-names>JA</given-names></name><name><surname>Allen</surname><given-names>NE</given-names></name><name><surname>Groeller</surname><given-names>H</given-names></name></person-group>. <article-title>Parkinson&#x2019;s disease: an investigation of exercise capacity, respiratory function, and gait.</article-title> <source>Arch Phys Med Rehabil</source>. <year>1997</year>;<volume>78</volume>(<issue>2</issue>):<fpage>199</fpage>&#x2013;<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1016/S0003-9993(97)90264-1</pub-id><pub-id pub-id-type="pmid">9041903</pub-id></mixed-citation></ref>
<ref id="r44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canning</surname><given-names>CG</given-names></name><name><surname>Ada</surname><given-names>L</given-names></name><name><surname>Johnson</surname><given-names>JJ</given-names></name><name><surname>McWhirter</surname><given-names>S</given-names></name></person-group>. <article-title>Walking capacity in mild to moderate Parkinson&#x2019;s disease.</article-title> <source>Arch Phys Med Rehabil</source>. <year>2006</year>;<volume>87</volume>(<issue>3</issue>):<fpage>371</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.apmr.2005.11.021</pub-id><pub-id pub-id-type="pmid">16500171</pub-id></mixed-citation></ref>
<ref id="r45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cugusi</surname><given-names>L</given-names></name><name><surname>Solla</surname><given-names>P</given-names></name><name><surname>Serpe</surname><given-names>R</given-names></name><name><surname>Carzedda</surname><given-names>T</given-names></name><name><surname>Piras</surname><given-names>L</given-names></name><name><surname>Oggianu</surname><given-names>M</given-names></name><etal/></person-group> <article-title>Effects of a Nordic Walking program on motor and non-motor symptoms, functional performance and body composition in patients with Parkinson&#x2019;s disease.</article-title> <source>NeuroRehabilitation</source>. <year>2015</year>;<volume>37</volume>(<issue>2</issue>):<fpage>245</fpage>&#x2013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.3233/NRE-151257</pub-id><pub-id pub-id-type="pmid">26484516</pub-id></mixed-citation></ref>
<ref id="r46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shulman</surname><given-names>LM</given-names></name><name><surname>Katzel</surname><given-names>LI</given-names></name><name><surname>Ivey</surname><given-names>FM</given-names></name><name><surname>Sorkin</surname><given-names>JD</given-names></name><name><surname>Favors</surname><given-names>K</given-names></name><name><surname>Anderson</surname><given-names>KE</given-names></name><etal/></person-group> <article-title>Randomized clinical trial of 3 types of physical exercise for patients with Parkinson disease.</article-title> <source>JAMA Neurol</source>. <year>2013</year>;<volume>70</volume>(<issue>2</issue>):<fpage>183</fpage>&#x2013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1001/jamaneurol.2013.646</pub-id><pub-id pub-id-type="pmid">23128427</pub-id></mixed-citation></ref>
<ref id="r47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uc</surname><given-names>EY</given-names></name><name><surname>Doerschug</surname><given-names>KC</given-names></name><name><surname>Magnotta</surname><given-names>V</given-names></name><name><surname>Dawson</surname><given-names>JD</given-names></name><name><surname>Thomsen</surname><given-names>TR</given-names></name><name><surname>Kline</surname><given-names>JN</given-names></name><etal/></person-group> <article-title>Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting.</article-title> <source>Neurology</source>. <year>2014</year>;<volume>83</volume>(<issue>5</issue>):<fpage>413</fpage>&#x2013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000000644</pub-id><pub-id pub-id-type="pmid">24991037</pub-id></mixed-citation></ref>
<ref id="r48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schenkman</surname><given-names>M</given-names></name><name><surname>Hall</surname><given-names>DA</given-names></name><name><surname>Bar&#x00F3;n</surname><given-names>AE</given-names></name><name><surname>Schwartz</surname><given-names>RS</given-names></name><name><surname>Mettler</surname><given-names>P</given-names></name><name><surname>Kohrt</surname><given-names>WM</given-names></name></person-group>. <article-title>Exercise for people in early- or mid-stage Parkinson disease: a 16-month randomized controlled trial.</article-title> <source>Phys Ther</source>. <year>2012</year>;<volume>92</volume>(<issue>11</issue>):<fpage>1395</fpage>&#x2013;<lpage>410</lpage>. <pub-id pub-id-type="doi">10.2522/ptj.20110472</pub-id><pub-id pub-id-type="pmid">22822237</pub-id></mixed-citation></ref>
<ref id="r49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picelli</surname><given-names>A</given-names></name><name><surname>Varalta</surname><given-names>V</given-names></name><name><surname>Melotti</surname><given-names>C</given-names></name><name><surname>Zatezalo</surname><given-names>V</given-names></name><name><surname>Fonte</surname><given-names>C</given-names></name><name><surname>Amato</surname><given-names>S</given-names></name><etal/></person-group> <article-title>Effects of treadmill training on cognitive and motor features of patients with mild to moderate Parkinson&#x2019;s disease: a pilot, single-blind, randomized controlled trial.</article-title> <source>Funct Neurol</source>. <year>2016</year>;<volume>31</volume>(<issue>1</issue>):<fpage>25</fpage>&#x2013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">27027891</pub-id></mixed-citation></ref>
<ref id="r50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dibble</surname><given-names>LE</given-names></name><name><surname>Foreman</surname><given-names>KB</given-names></name><name><surname>Addison</surname><given-names>O</given-names></name><name><surname>Marcus</surname><given-names>RL</given-names></name><name><surname>LaStayo</surname><given-names>PC</given-names></name></person-group>. <article-title>Exercise and medication effects on persons with Parkinson disease across the domains of disability: a randomized clinical trial.</article-title> <source>J Neurol Phys Ther</source>. <year>2015</year>;<volume>39</volume>(<issue>2</issue>):<fpage>85</fpage>&#x2013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1097/NPT.0000000000000086</pub-id><pub-id pub-id-type="pmid">25742370</pub-id></mixed-citation></ref>
<ref id="r51"><label>51</label><mixed-citation publication-type="other">Kelly NA, Ford MP, Standaert DG, Watts RL, Bickel CS, Moellering DR, et al. Novel, high-intensity exercise prescription improves muscle mass, mitochondrial function, and physical capacity in individuals with Parkinson&#x2019;s disease. J Appl Physiol (1985). 2014;116(5):582&#x2013;92.</mixed-citation></ref>
<ref id="r52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>FJ</given-names></name><name><surname>Robichaud</surname><given-names>JA</given-names></name><name><surname>Vaillancourt</surname><given-names>DE</given-names></name><name><surname>Poon</surname><given-names>C</given-names></name><name><surname>Kohrt</surname><given-names>WM</given-names></name><name><surname>Comella</surname><given-names>CL</given-names></name><etal/></person-group> <article-title>Progressive resistance exercise restores some properties of the triphasic EMG pattern and improves bradykinesia: the PRET-PD randomized clinical trial.</article-title> <source>J Neurophysiol</source>. <year>2016</year>;<volume>116</volume>(<issue>5</issue>):<fpage>2298</fpage>&#x2013;<lpage>311</lpage>. <pub-id pub-id-type="doi">10.1152/jn.01067.2015</pub-id><pub-id pub-id-type="pmid">27582297</pub-id></mixed-citation></ref>
<ref id="r53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corcos</surname><given-names>DM</given-names></name><name><surname>Robichaud</surname><given-names>JA</given-names></name><name><surname>David</surname><given-names>FJ</given-names></name><name><surname>Leurgans</surname><given-names>SE</given-names></name><name><surname>Vaillancourt</surname><given-names>DE</given-names></name><name><surname>Poon</surname><given-names>C</given-names></name><etal/></person-group> <article-title>A two-year randomized controlled trial of progressive resistance exercise for Parkinson&#x2019;s disease.</article-title> <source>Mov Disord</source>. <year>2013</year>;<volume>28</volume>(<issue>9</issue>):<fpage>1230</fpage>&#x2013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1002/mds.25380</pub-id><pub-id pub-id-type="pmid">23536417</pub-id></mixed-citation></ref>
<ref id="r54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svehl&#x00ED;k</surname><given-names>M</given-names></name><name><surname>Zwick</surname><given-names>EB</given-names></name><name><surname>Steinwender</surname><given-names>G</given-names></name><name><surname>Linhart</surname><given-names>WE</given-names></name><name><surname>Schwingenschuh</surname><given-names>P</given-names></name><name><surname>Katschnig</surname><given-names>P</given-names></name><etal/></person-group> <article-title>Gait analysis in patients with Parkinson&#x2019;s disease off dopaminergic therapy.</article-title> <source>Arch Phys Med Rehabil</source>. <year>2009</year>;<volume>90</volume>(<issue>11</issue>):<fpage>1880</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.apmr.2009.06.017</pub-id><pub-id pub-id-type="pmid">19887212</pub-id></mixed-citation></ref>
<ref id="r55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Emmerik</surname><given-names>RE</given-names></name><name><surname>Wagenaar</surname><given-names>RC</given-names></name><name><surname>Winogrodzka</surname><given-names>A</given-names></name><name><surname>Wolters</surname><given-names>EC</given-names></name></person-group>. <article-title>Identification of axial rigidity during locomotion in Parkinson disease.</article-title> <source>Arch Phys Med Rehabil</source>. <year>1999</year>;<volume>80</volume>(<issue>2</issue>):<fpage>186</fpage>&#x2013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1016/S0003-9993(99)90119-3</pub-id><pub-id pub-id-type="pmid">10025495</pub-id></mixed-citation></ref>
<ref id="r56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hausdorff</surname><given-names>JM</given-names></name><name><surname>Cudkowicz</surname><given-names>ME</given-names></name><name><surname>Firtion</surname><given-names>R</given-names></name><name><surname>Wei</surname><given-names>JY</given-names></name><name><surname>Goldberger</surname><given-names>AL</given-names></name></person-group>. <article-title>Gait variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in Parkinson&#x2019;s disease and Huntington&#x2019;s disease.</article-title> <source>Mov Disord</source>. <year>1998</year>;<volume>13</volume>(<issue>3</issue>):<fpage>428</fpage>&#x2013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1002/mds.870130310</pub-id><pub-id pub-id-type="pmid">9613733</pub-id></mixed-citation></ref>
<ref id="r57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadeau</surname><given-names>A</given-names></name><name><surname>Pourcher</surname><given-names>E</given-names></name><name><surname>Corbeil</surname><given-names>P</given-names></name></person-group>. <article-title>Effects of 24 wk of treadmill training on gait performance in Parkinson&#x2019;s disease.</article-title> <source>Med Sci Sports Exerc</source>. <year>2014</year>;<volume>46</volume>(<issue>4</issue>):<fpage>645</fpage>&#x2013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1249/MSS.0000000000000144</pub-id><pub-id pub-id-type="pmid">24002341</pub-id></mixed-citation></ref>
<ref id="r58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghai</surname><given-names>S</given-names></name><name><surname>Ghai</surname><given-names>I</given-names></name><name><surname>Schmitz</surname><given-names>G</given-names></name><name><surname>Effenberg</surname><given-names>AO</given-names></name></person-group>. <article-title>Effect of rhythmic auditory cueing on parkinsonian gait: A systematic review and meta-analysis.</article-title> <source>Sci Rep</source>. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>506</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-16232-5</pub-id><pub-id pub-id-type="pmid">29323122</pub-id></mixed-citation></ref>
<ref id="r59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginis</surname><given-names>P</given-names></name><name><surname>Nackaerts</surname><given-names>E</given-names></name><name><surname>Nieuwboer</surname><given-names>A</given-names></name><name><surname>Heremans</surname><given-names>E</given-names></name></person-group>. <article-title>Cueing for people with Parkinson&#x2019;s disease with freezing of gait: A narrative review of the state-of-the-art and novel perspectives.</article-title> <source>Ann Phys Rehabil Med</source>. <year>2018</year>;<volume>61</volume>(<issue>6</issue>):<fpage>407</fpage>&#x2013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.rehab.2017.08.002</pub-id><pub-id pub-id-type="pmid">28890341</pub-id></mixed-citation></ref>
<ref id="r60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leddy</surname><given-names>AL</given-names></name><name><surname>Crowner</surname><given-names>BE</given-names></name><name><surname>Earhart</surname><given-names>GM</given-names></name></person-group>. <article-title>Utility of the Mini-BESTest, BESTest, and BESTest sections for balance assessments in individuals with Parkinson disease.</article-title> <source>J Neurol Phys Ther</source>. <year>2011</year>;<volume>35</volume>(<issue>2</issue>):<fpage>90</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1097/NPT.0b013e31821a620c</pub-id><pub-id pub-id-type="pmid">21934364</pub-id></mixed-citation></ref>
<ref id="r61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancini</surname><given-names>M</given-names></name><name><surname>Carlson-Kuhta</surname><given-names>P</given-names></name><name><surname>Zampieri</surname><given-names>C</given-names></name><name><surname>Nutt</surname><given-names>JG</given-names></name><name><surname>Chiari</surname><given-names>L</given-names></name><name><surname>Horak</surname><given-names>FB</given-names></name></person-group>. <article-title>Postural sway as a marker of progression in Parkinson&#x2019;s disease: a pilot longitudinal study.</article-title> <source>Gait Posture</source>. <year>2012</year>;<volume>36</volume>(<issue>3</issue>):<fpage>471</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.gaitpost.2012.04.010</pub-id><pub-id pub-id-type="pmid">22750016</pub-id></mixed-citation></ref>
<ref id="r62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancini</surname><given-names>M</given-names></name><name><surname>Rocchi</surname><given-names>L</given-names></name><name><surname>Horak</surname><given-names>FB</given-names></name><name><surname>Chiari</surname><given-names>L</given-names></name></person-group>. <article-title>Effects of Parkinson&#x2019;s disease and levodopa on functional limits of stability.</article-title> <source>Clin Biomech (Bristol, Avon)</source>. <year>2008</year>;<volume>23</volume>(<issue>4</issue>):<fpage>450</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.clinbiomech.2007.11.007</pub-id><pub-id pub-id-type="pmid">18155331</pub-id></mixed-citation></ref>
<ref id="r63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boonstra</surname><given-names>TA</given-names></name><name><surname>van Kordelaar</surname><given-names>J</given-names></name><name><surname>Engelhart</surname><given-names>D</given-names></name><name><surname>van Vugt</surname><given-names>JP</given-names></name><name><surname>van der Kooij</surname><given-names>H</given-names></name></person-group>. <article-title>Asymmetries in reactive and anticipatory balance control are of similar magnitude in Parkinson&#x2019;s disease patients.</article-title> <source>Gait Posture</source>. <year>2016</year>;<volume>43</volume>:<fpage>108</fpage>&#x2013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.gaitpost.2015.08.014</pub-id><pub-id pub-id-type="pmid">26475760</pub-id></mixed-citation></ref>
<ref id="r64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roemmich</surname><given-names>RT</given-names></name><name><surname>Nocera</surname><given-names>JR</given-names></name><name><surname>Vallabhajosula</surname><given-names>S</given-names></name><name><surname>Amano</surname><given-names>S</given-names></name><name><surname>Naugle</surname><given-names>KM</given-names></name><name><surname>Stegem&#x00F6;ller</surname><given-names>EL</given-names></name><etal/></person-group> <article-title>Spatiotemporal variability during gait initiation in Parkinson&#x2019;s disease.</article-title> <source>Gait Posture</source>. <year>2012</year>;<volume>36</volume>(<issue>3</issue>):<fpage>340</fpage>&#x2013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/j.gaitpost.2012.01.018</pub-id><pub-id pub-id-type="pmid">22543093</pub-id></mixed-citation></ref>
<ref id="r65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>MW</given-names></name><name><surname>Kennedy</surname><given-names>R</given-names></name><name><surname>Palmer</surname><given-names>S</given-names></name><name><surname>Pawar</surname><given-names>M</given-names></name><name><surname>Reising</surname><given-names>M</given-names></name><name><surname>Martinez</surname><given-names>KM</given-names></name><etal/></person-group> <article-title>Postural preparation prior to stepping in patients with Parkinson&#x2019;s disease.</article-title> <source>J Neurophysiol</source>. <year>2011</year>;<volume>106</volume>(<issue>2</issue>):<fpage>915</fpage>&#x2013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1152/jn.00005.2010</pub-id><pub-id pub-id-type="pmid">21525376</pub-id></mixed-citation></ref>
<ref id="r66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>LA</given-names></name><name><surname>Horak</surname><given-names>FB</given-names></name></person-group>. <article-title>Lateral stepping for postural correction in Parkinson&#x2019;s disease.</article-title> <source>Arch Phys Med Rehabil</source>. <year>2008</year>;<volume>89</volume>(<issue>3</issue>):<fpage>492</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.apmr.2007.11.017</pub-id><pub-id pub-id-type="pmid">18295628</pub-id></mixed-citation></ref>
<ref id="r67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloem</surname><given-names>BR</given-names></name><name><surname>Grimbergen</surname><given-names>YA</given-names></name><name><surname>Cramer</surname><given-names>M</given-names></name><name><surname>Willemsen</surname><given-names>M</given-names></name><name><surname>Zwinderman</surname><given-names>AH</given-names></name></person-group>. <article-title>Prospective assessment of falls in Parkinson&#x2019;s disease.</article-title> <source>J Neurol</source>. <year>2001</year>;<volume>248</volume>(<issue>11</issue>):<fpage>950</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s004150170047</pub-id><pub-id pub-id-type="pmid">11757958</pub-id></mixed-citation></ref>
<ref id="r68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloem</surname><given-names>BR</given-names></name><name><surname>Hausdorff</surname><given-names>J</given-names></name><name><surname>Visser</surname><given-names>JE</given-names></name><name><surname>Giladi</surname><given-names>N</given-names></name></person-group>. <article-title>Falls and freezing of gait in Parkinson&#x2019;s disease: a review of two interconnected, episodic phenomena.</article-title> <source>Mov Disord</source>. <year>2004</year>;<volume>19</volume>(<issue>8</issue>):<fpage>871</fpage>&#x2013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1002/mds.20115</pub-id><pub-id pub-id-type="pmid">15300651</pub-id></mixed-citation></ref>
<ref id="r69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashburn</surname><given-names>A</given-names></name><name><surname>Stack</surname><given-names>E</given-names></name><name><surname>Pickering</surname><given-names>RM</given-names></name><name><surname>Ward</surname><given-names>CD</given-names></name></person-group>. <article-title>Predicting fallers in a community-based sample of people with Parkinson&#x2019;s disease.</article-title> <source>Gerontology</source>. <year>2001</year>;<volume>47</volume>(<issue>5</issue>):<fpage>277</fpage>&#x2013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1159/000052812</pub-id><pub-id pub-id-type="pmid">11490147</pub-id></mixed-citation></ref>
<ref id="r70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dennison</surname><given-names>AC</given-names></name><name><surname>Noorigian</surname><given-names>JV</given-names></name><name><surname>Robinson</surname><given-names>KM</given-names></name><name><surname>Fisman</surname><given-names>DN</given-names></name><name><surname>Cianci</surname><given-names>HJ</given-names></name><name><surname>Moberg</surname><given-names>P</given-names></name><etal/></person-group> <article-title>Falling in Parkinson disease: identifying and prioritizing risk factors in recurrent fallers.</article-title> <source>Am J Phys Med Rehabil</source>. <year>2007</year>;<volume>86</volume>(<issue>8</issue>):<fpage>621</fpage>&#x2013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1097/PHM.0b013e311611583</pub-id><pub-id pub-id-type="pmid">17667192</pub-id></mixed-citation></ref>
<ref id="r71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerr</surname><given-names>GK</given-names></name><name><surname>Worringham</surname><given-names>CJ</given-names></name><name><surname>Cole</surname><given-names>MH</given-names></name><name><surname>Lacherez</surname><given-names>PF</given-names></name><name><surname>Wood</surname><given-names>JM</given-names></name><name><surname>Silburn</surname><given-names>PA</given-names></name></person-group>. <article-title>Predictors of future falls in Parkinson disease.</article-title> <source>Neurology</source>. <year>2010</year>;<volume>75</volume>(<issue>2</issue>):<fpage>116</fpage>&#x2013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0b013e3181e7b688</pub-id><pub-id pub-id-type="pmid">20574039</pub-id></mixed-citation></ref>
<ref id="r72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mak</surname><given-names>MK</given-names></name><name><surname>Pang</surname><given-names>MY</given-names></name></person-group>. <article-title>Fear of falling is independently associated with recurrent falls in patients with Parkinson&#x2019;s disease: a 1-year prospective study.</article-title> <source>J Neurol</source>. <year>2009</year>;<volume>256</volume>(<issue>10</issue>):<fpage>1689</fpage>&#x2013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1007/s00415-009-5184-5</pub-id><pub-id pub-id-type="pmid">19479166</pub-id></mixed-citation></ref>
<ref id="r73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloem</surname><given-names>BR</given-names></name><name><surname>Hausdorff</surname><given-names>J</given-names></name><name><surname>Visser</surname><given-names>JE</given-names></name><name><surname>Giladi</surname><given-names>N</given-names></name></person-group>. <article-title>Falls and freezing of gait in Parkinson&#x2019;s disease: a review of two interconnected, episodic phenomena.</article-title> <source>Mov Disord</source>. <year>2004</year>;<volume>19</volume>(<issue>8</issue>):<fpage>871</fpage>&#x2013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1002/mds.20115</pub-id><pub-id pub-id-type="pmid">15300651</pub-id></mixed-citation></ref>
<ref id="r74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>NE</given-names></name><name><surname>Canning</surname><given-names>CG</given-names></name><name><surname>Sherrington</surname><given-names>C</given-names></name><name><surname>Lord</surname><given-names>SR</given-names></name><name><surname>Latt</surname><given-names>MD</given-names></name><name><surname>Close</surname><given-names>JC</given-names></name><etal/></person-group> <article-title>The effects of an exercise program on fall risk factors in people with Parkinson&#x2019;s disease: a randomized controlled trial.</article-title> <source>Mov Disord</source>. <year>2010</year>;<volume>25</volume>(<issue>9</issue>):<fpage>1217</fpage>&#x2013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1002/mds.23082</pub-id><pub-id pub-id-type="pmid">20629134</pub-id></mixed-citation></ref>
<ref id="r75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nutt</surname><given-names>JG</given-names></name><name><surname>Bloem</surname><given-names>BR</given-names></name><name><surname>Giladi</surname><given-names>N</given-names></name><name><surname>Hallett</surname><given-names>M</given-names></name><name><surname>Horak</surname><given-names>FB</given-names></name><name><surname>Nieuwboer</surname><given-names>A</given-names></name></person-group>. <article-title>Freezing of gait: moving forward on a mysterious clinical phenomenon.</article-title> <source>Lancet Neurol</source>. <year>2011</year>;<volume>10</volume>(<issue>8</issue>):<fpage>734</fpage>&#x2013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(11)70143-0</pub-id><pub-id pub-id-type="pmid">21777828</pub-id></mixed-citation></ref>
<ref id="r76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>del Olmo</surname><given-names>MF</given-names></name><name><surname>Arias</surname><given-names>P</given-names></name><name><surname>Furio</surname><given-names>MC</given-names></name><name><surname>Pozo</surname><given-names>MA</given-names></name><name><surname>Cudeiro</surname><given-names>J</given-names></name></person-group>. <article-title>Evaluation of the effect of training using auditory stimulation on rhythmic movement in Parkinsonian patients--a combined motor and [18F]-FDG PET study.</article-title> <source>Parkinsonism Relat Disord</source>. <year>2006</year>;<volume>12</volume>(<issue>3</issue>):<fpage>155</fpage>&#x2013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.parkreldis.2005.11.002</pub-id><pub-id pub-id-type="pmid">16459124</pub-id></mixed-citation></ref>
<ref id="r77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>R</given-names></name><name><surname>Grabowska</surname><given-names>W</given-names></name><name><surname>Park</surname><given-names>M</given-names></name><name><surname>Osypiuk</surname><given-names>K</given-names></name><name><surname>Vergara-Diaz</surname><given-names>GP</given-names></name><name><surname>Bonato</surname><given-names>P</given-names></name><etal/></person-group> <article-title>The impact of Tai Chi and Qigong mind-body exercises on motor and non-motor function and quality of life in Parkinson&#x2019;s disease: A systematic review and meta-analysis.</article-title> <source>Parkinsonism Relat Disord</source>. <year>2017</year>;<volume>41</volume>:<fpage>3</fpage>&#x2013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.parkreldis.2017.05.019</pub-id><pub-id pub-id-type="pmid">28602515</pub-id></mixed-citation></ref>
<ref id="r78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwok</surname><given-names>JYY</given-names></name><name><surname>Kwan</surname><given-names>JCY</given-names></name><name><surname>Auyeung</surname><given-names>M</given-names></name><name><surname>Mok</surname><given-names>VCT</given-names></name><name><surname>Lau</surname><given-names>CKY</given-names></name><name><surname>Choi</surname><given-names>KC</given-names></name><etal/></person-group> <article-title>Effects of Mindfulness Yoga vs Stretching and Resistance Training Exercises on Anxiety and Depression for People With Parkinson Disease: A Randomized Clinical Trial.</article-title> <source>JAMA Neurol</source>. <year>2019</year>;<volume>76</volume>(<issue>7</issue>):<fpage>755</fpage>&#x2013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1001/jamaneurol.2019.0534</pub-id><pub-id pub-id-type="pmid">30958514</pub-id></mixed-citation></ref>
<ref id="r79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frazzitta</surname><given-names>G</given-names></name><name><surname>Maestri</surname><given-names>R</given-names></name><name><surname>Bertotti</surname><given-names>G</given-names></name><name><surname>Riboldazzi</surname><given-names>G</given-names></name><name><surname>Boveri</surname><given-names>N</given-names></name><name><surname>Perini</surname><given-names>M</given-names></name><etal/></person-group> <article-title>Intensive rehabilitation treatment in early Parkinson&#x2019;s disease: a randomized pilot study with a 2-year follow-up.</article-title> <source>Neurorehabil Neural Repair</source>. <year>2015</year>;<volume>29</volume>(<issue>2</issue>):<fpage>123</fpage>&#x2013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1177/1545968314542981</pub-id><pub-id pub-id-type="pmid">25038064</pub-id></mixed-citation></ref>
<ref id="r80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javier</surname><given-names>NS</given-names></name><name><surname>Montagnini</surname><given-names>ML</given-names></name></person-group>. <article-title>Rehabilitation of the hospice and palliative care patient.</article-title> <source>J Palliat Med</source>. <year>2011</year>;<volume>14</volume>(<issue>5</issue>):<fpage>638</fpage>&#x2013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1089/jpm.2010.0125</pub-id><pub-id pub-id-type="pmid">21592031</pub-id></mixed-citation></ref>
<ref id="r81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welsby</surname><given-names>E</given-names></name><name><surname>Berrigan</surname><given-names>S</given-names></name><name><surname>Laver</surname><given-names>K</given-names></name></person-group>. <article-title>Effectiveness of occupational therapy intervention for people with Parkinson&#x2019;s disease: Systematic review.</article-title> <source>Aust Occup Ther J</source>. <year>2019</year>;<volume>66</volume>(<issue>6</issue>):<fpage>731</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/1440-1630.12615</pub-id><pub-id pub-id-type="pmid">31599467</pub-id></mixed-citation></ref>
<ref id="r82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sturkenboom</surname><given-names>IH</given-names></name><name><surname>Graff</surname><given-names>MJ</given-names></name><name><surname>Hendriks</surname><given-names>JC</given-names></name><name><surname>Veenhuizen</surname><given-names>Y</given-names></name><name><surname>Munneke</surname><given-names>M</given-names></name><name><surname>Bloem</surname><given-names>BR</given-names></name><etal/></person-group> <article-title>Efficacy of occupational therapy for patients with Parkinson&#x2019;s disease: a randomised controlled trial.</article-title> <source>Lancet Neurol</source>. <year>2014</year>;<volume>13</volume>(<issue>6</issue>):<fpage>557</fpage>&#x2013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(14)70055-9</pub-id><pub-id pub-id-type="pmid">24726066</pub-id></mixed-citation></ref>
<ref id="r83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trail</surname><given-names>M</given-names></name><name><surname>Fox</surname><given-names>C</given-names></name><name><surname>Ramig</surname><given-names>LO</given-names></name><name><surname>Sapir</surname><given-names>S</given-names></name><name><surname>Howard</surname><given-names>J</given-names></name><name><surname>Lai</surname><given-names>EC</given-names></name></person-group>. <article-title>Speech treatment for Parkinson&#x2019;s disease.</article-title> <source>NeuroRehabilitation</source>. <year>2005</year>;<volume>20</volume>(<issue>3</issue>):<fpage>205</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.3233/NRE-2005-20307</pub-id><pub-id pub-id-type="pmid">16340101</pub-id></mixed-citation></ref>
<ref id="r84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suchowersky</surname><given-names>O</given-names></name><name><surname>Gronseth</surname><given-names>G</given-names></name><name><surname>Perlmutter</surname><given-names>J</given-names></name><name><surname>Reich</surname><given-names>S</given-names></name><name><surname>Zesiewicz</surname><given-names>T</given-names></name><name><surname>Weiner</surname><given-names>WJ</given-names></name></person-group>. <article-title>Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.</article-title> <source>Neurology</source>. <year>2006</year>;<volume>66</volume>(<issue>7</issue>):<fpage>976</fpage>&#x2013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1212/01.wnl.0000206363.57955.1b</pub-id><pub-id pub-id-type="pmid">16606908</pub-id></mixed-citation></ref>
<ref id="r85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramig</surname><given-names>LO</given-names></name><name><surname>Sapir</surname><given-names>S</given-names></name><name><surname>Countryman</surname><given-names>S</given-names></name><name><surname>Pawlas</surname><given-names>AA</given-names></name><name><surname>O&#x2019;Brien</surname><given-names>C</given-names></name><name><surname>Hoehn</surname><given-names>M</given-names></name><etal/></person-group> <article-title>Intensive voice treatment (LSVT) for patients with Parkinson&#x2019;s disease: a 2 year follow up.</article-title> <source>J Neurol Neurosurg Psychiatry</source>. <year>2001</year>;<volume>71</volume>(<issue>4</issue>):<fpage>493</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1136/jnnp.71.4.493</pub-id><pub-id pub-id-type="pmid">11561033</pub-id></mixed-citation></ref>
</ref-list>
</back>
</article>
